Author: "Hirsch, HH." - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Hirsch, HH."' showing total 554 results

Start Over Author "Hirsch, HH."

554 results on '"Hirsch, HH."'

1. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland

Author: Abela, I, Aebi-Popp, K, Anagnostopoulos, A, Battegay, M, Bernasconi, E, Braun, DL, Bucher, HC, Calmy, A, Cavassini, M, Ciuffi, A, Dollenmaier, G, Egger, M, Elzi, L, Fehr, J, Fellay, J, Furrer, H, Fux, CA, Günthard, HF, Hachfeld, A, Haerry, D, Hasse, B, Hirsch, HH, Hoffmann, M, Hösli, I, Huber, M, Jackson-Perry, D, Kahlert, CR, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, RD, Kovari, H, Kusejko, K, Labhardt, N, Leuzinger, K, Martinez de Tejada, B, Marzolini, C, Metzner, KJ, Müller, N, Nemeth, J, Nicca, D, Notter, J, Paioni, P, Pantaleo, G, Perreau, M, Rauch, A, Salazar-Vizcaya, L, Schmid, P, Speck, R, Stöckle, M, Tarr, P, Trkola, A, Wandeler, G, Weisser, M, Yerly, S, Thoueille, Paul, Saldanha, Susana Alves, Schaller, Fabian, Choong, Eva, Munting, Aline, Cavassini, Matthias, Braun, Dominique, Günthard, Huldrych F., Kusejko, Katharina, Surial, Bernard, Furrer, Hansjakob, Rauch, Andri, Rougemont, Mathieu, Ustero, Pilar, Calmy, Alexandra, Stöckle, Marcel, Marzolini, Catia, Di Benedetto, Caroline, Bernasconi, Enos, Schmid, Patrick, Piso, Rein Jan, Andre, Pascal, Girardin, François R., Guidi, Monia, Buclin, Thierry, and Decosterd, Laurent A.
Published: 2024
Full Text: View/download PDF

2. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study.

Author: Vincenti, Flavio, Hirsch, HH, Friman, S, Tuncer, M, Citterio, F, Wiecek, A, Scheuermann, EH, Klinger, M, Russ, G, and Pescovitz, MD
Abstract: Polyomavirus BK (BKV)-associated nephropathy causes premature kidney transplant (KT) failure. BKV viruria and viremia are biomarkers of disease progression, but associated risk factors are controversial. A total of 682 KT patients receiving basiliximab, my
Published: 2013

3. Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study

Author: Bayard, Cornelia, Ledergerber, Bruno, Flepp, Markus, Lecompte, Thanh, Moulin, Estelle, Hoffmann, Matthias, Weber, Rainer, Staehelin, Cornelia, Di Benedetto, Caroline, Fux, Christoph A, Tarr, Philip E, Hasse, Barbara, Aubert, V, Battegay, M, Bernasconi, E, Böni, J, Braun, DL, Bucher, HC, Calmy, A, Cavassini, M, Ciuffi, A, Dollenmaier, G, Egger, M, Elzi, L, Fehr, J, Fellay, J, Furrer, H, Fux, CA, Günthard, HF, Haerry, D, Hasse, B, Hirsch, HH, Hoffmann, M, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, RD, Kovari, H, Ledergerber, B, Martinetti, G, Martinez de Tejada, B, Marzolini, C, Metzner, KJ, Müller, N, Nicca, D, Pantaleo, G, Paioni, P, Rauch, A, Rudin, C, Scherrer, AU, Schmid, P, Speck, R, Stöckle, M, Tarr, P, Trkola, A, Vernazza, P, Wandeler, G, Weber, R, and Yerly, S
Published: 2017
Full Text: View/download PDF

4. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study

Author: Béguelin, Charles, Suter, Annatina, Bernasconi, Enos, Fehr, Jan, Kovari, Helen, Bucher, Heiner C., Stoeckle, Marcel, Cavassini, Mathias, Rougemont, Mathieu, Schmid, Patrick, Wandeler, Gilles, Rauch, Andri, Aubert, V, Battegay, M, Böni, J, Braun, DL, Calmy, A, Ciuffi, A, Dollenmaier, G, Egger, M, Elzi, L, Fellay, J, Furrer, H, Fux, CA, Günthard, HF, Haerry, D, Hasse, B, Hirsch, HH, Hoffmann, M, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, RD, Ledergerber, B, Martinetti, G, Tejada, B, Marzolini, C, Metzner, KJ, Müller, N, Nicca, D, Pantaleo, G, Paioni, P, Rudin, C, Scherrer, AU, Speck, R, Stöckle, M, Tarr, P, Trkola, A, Vernazza, P, Weber, R, and Yerly, S
Published: 2018
Full Text: View/download PDF

5. Determinants of SARS-CoV-2 transmission to guide vaccination strategy in an urban area.

Author: Brüningk, SC, Klatt, J, Stange, M, Mari, A, Brunner, M, Roloff, T-C, Seth-Smith, HMB, Schweitzer, M, Leuzinger, K, Søgaard, KK, Albertos Torres, D, Gensch, A, Schlotterbeck, A-K, Nickel, CH, Ritz, N, Heininger, U, Bielicki, J, Rentsch, K, Fuchs, S, Bingisser, R, Siegemund, M, Pargger, H, Ciardo, D, Dubuis, O, Buser, A, Tschudin-Sutter, S, Battegay, M, Schneider-Sliwa, R, Borgwardt, KM, Hirsch, HH, Egli, A, Brüningk, SC, Klatt, J, Stange, M, Mari, A, Brunner, M, Roloff, T-C, Seth-Smith, HMB, Schweitzer, M, Leuzinger, K, Søgaard, KK, Albertos Torres, D, Gensch, A, Schlotterbeck, A-K, Nickel, CH, Ritz, N, Heininger, U, Bielicki, J, Rentsch, K, Fuchs, S, Bingisser, R, Siegemund, M, Pargger, H, Ciardo, D, Dubuis, O, Buser, A, Tschudin-Sutter, S, Battegay, M, Schneider-Sliwa, R, Borgwardt, KM, Hirsch, HH, and Egli, A
Abstract: Transmission chains within small urban areas (accommodating ∼30 per cent of the European population) greatly contribute to case burden and economic impact during the ongoing coronavirus pandemic and should be a focus for preventive measures to achieve containment. Here, at very high spatio-temporal resolution, we analysed determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission in a European urban area, Basel-City (Switzerland). We combined detailed epidemiological, intra-city mobility and socio-economic data sets with whole-genome sequencing during the first SARS-CoV-2 wave. For this, we succeeded in sequencing 44 per cent of all reported cases from Basel-City and performed phylogenetic clustering and compartmental modelling based on the dominating viral variant (B.1-C15324T; 60 per cent of cases) to identify drivers and patterns of transmission. Based on these results we simulated vaccination scenarios and corresponding healthcare system burden (intensive care unit (ICU) occupancy). Transmissions were driven by socio-economically weaker and highly mobile population groups with mostly cryptic transmissions which lacked genetic and identifiable epidemiological links. Amongst more senior population transmission was clustered. Simulated vaccination scenarios assuming 60-90 per cent transmission reduction and 70-90 per cent reduction of severe cases showed that prioritising mobile, socio-economically weaker populations for vaccination would effectively reduce case numbers. However, long-term ICU occupation would also be effectively reduced if senior population groups were prioritised, provided there were no changes in testing and prevention strategies. Reducing SARS-CoV-2 transmission through vaccination strongly depends on the efficacy of the deployed vaccine. A combined strategy of protecting risk groups by extensive testing coupled with vaccination of the drivers of transmission (i.e. highly mobile groups) would be most effective at
Published: 2022

6. Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017

Author: Ruffieux, Yann, Lemsalu, Liis, Aebi?Popp, Karoline, Calmy, Alexandra, Cavassini, Matthias, Fux, Christoph A., Günthard, Huldrych F., Marzolini, Catia, Scherrer, Alexandra, Vernazza, Pietro, Keiser, Olivia, Egger, Matthias, Anagnostopoulos, A., Battegay, M., Bernasconi, E., Böni, J., Braun, Dl., Bucher, Hc., Ciuffi, A., Dollenmaier, G., Elzi, L., Fehr, J., Fellay, J., Furrer, H., Haerry, D., Hasse, B., Hirsch, Hh., Hoffmann, M., Hösli, I., Huber, M., Kahlert, Cr., Kaiser, L., Klimkait, T., Kouyos, Rd., Kovari, H., Ledergerber, B., Martinetti, G., De Tejada, B. Martinez, Metzner, Kj., Müller, N., Nicca, D., Paioni, P., Pantaleo, G., Perreau, M., Rauch, A., Rudin, C., Schmid, P., Speck, R., Stöckle, M., Tarr, P., Trkola, A., Wandeler, G., Weber, R., and Yerly, S. Tbd.
Subjects: HIV patients -- Psychological aspects, Suicide -- Risk factors -- Statistics, Health
Abstract: : Introduction: In many countries, mortality due to suicide is higher among people living with HIV than in the general population. We aimed to analyse trends in suicide mortality before and after the introduction of triple combination antiretroviral therapy (cART), and to identify risk factors associated with death from suicide in Switzerland. Methods: We analysed data from the Swiss HIV Cohort Study from the pre‐cART (1988‐1995), earlier cART (1996‐2008) and later cART (2009‐2017) eras. We used multivariable Cox regression to assess risk factors for death due to suicide in the ART era and computed standardized mortality ratios (SMRs) to compare mortality rates due to suicide among persons living with HIV with the general population living in Switzerland, using data from the Swiss National Cohort. Results and Discussion: We included 20,136 persons living with HIV, of whom 204 (1.0%) died by suicide. In men, SMRs for suicide declined from 12.9 (95% CI 10.4‐16.0) in the pre‐cART era to 2.4 (95% CI 1.2‐5.1) in the earlier cART and 3.1 (95% CI 2.3‐4.3) in the later cART era. In women, the corresponding ratios declined from 14.2 (95% CI 7.9‐25.7) to 10.2 (3.8‐27.1) and to 3.3 (95% CI 1.5‐7.4). Factors associated with death due to suicide included gender (adjusted hazard ratio 0.58 (95% CI 0.38‐0.87) comparing women with men), nationality (1.95 (95% CI 1.34‐2.83) comparing Swiss with other), Centers for Disease Control and Prevention clinical stage (0.33 (95% CI 0.24‐0.46) comparing stage A with C), transmission group (2.64 (95% CI 1.71‐4.09) for injection drug use and 2.10 (95% CI 1.36‐3.24) for sex between men compared to other), and mental health (2.32 (95% CI 1.71‐3.14) for a history of psychiatric treatment vs. no history). There was no association with age. Conclusions: Suicide rates have decreased substantially among people living with HIV in the last three decades but have remained about three times higher than in the general population since the introduction of cART. Continued emphasis on suicide prevention among men and women living with HIV is important., Introduction Depression, anxiety and other mental health problems are common among people living with HIV, and more common than in the general population or among comparable HIV‐negative people. In the [...]
Published: 2019
Full Text: View/download PDF

7. Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals

Author: Barceló, Catalina, Gaspar, Frédéric, Aouri, Manel, Panchaud, Alice, Rotger, Margalida, Guidi, Monia, Cavassini, Matthias, Buclin, Thierry, Decosterd, Laurent A., Csajka, Chantal, Aubert, V., Battegay, M., Bernasconi, E., Böni, J., Braun, DL, Bucher, HC, Burton-Jeangros, C., Calmy, A., Cavassini, M., Dollenmaier, G., Egger, M., Elzi, L., Fehr, J., Fellay, J., Furrer, H., Fux, CA, Gorgievski, M., Günthard, H., Haerry, D., Hasse, B., Hirsch, HH, Hoffmann, M., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Klimkait, T., Kouyos, R., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Marzolini, C., Metzner, K., Müller, N., Nadal, D., Nicca, D., Pantaleo, G., Rauch, A., Regenass, S., Rudin, C., Schöni-Affolter, F., Schmid, P., Speck, R., Stöckle, M., Tarr, P., Trkola, A., Vernazza, P., Weber, R., and Yerly, S.
Subjects: virus diseases
Abstract: Objectives Co-formulated elvitegravir, cobicistat, tenofovir disoproxil fumarate and emtricitabine is among the preferred regimens for first-line ART. A population approach was used to characterize the pharmacokinetics of elvitegravir and cobicistat and identify individual factors and co-medications influencing their disposition, taking into consideration the interaction between the two compounds. Methods The study population included 144 HIV-infected individuals who provided 186 and 167 elvitegravir and cobicistat plasma concentrations, respectively. First, distinct NONMEM® analyses were conducted for elvitegravir and cobicistat, including individual demographic, clinical and genetic factors as potential covariates. Elvitegravir and cobicistat interaction was then assessed through different inhibitory models. Simulations based on the final model served to compare expected drug concentrations under standard and alternative dosage regimens. Results Clearance with between-subject variability was 7.6 L/h [coefficient of variation (CV) 16.6%] and volume of distribution 61 L for elvitegravir and 16.0 L/h (CV 41.9%) and 88.3 L, respectively, for cobicistat. Concomitant administration of non-ritonavir-boosted atazanavir decreased elvitegravir clearance by 35%, likely due to UDP-glucuronosyl transferase (UGT) 1A1 inhibition. Concomitant administration of non-ritonavir-boosted atazanavir and ritonavir-boosted darunavir decreased cobicistat clearance by 47% and 27%, respectively. The final interaction model included cobicistat exposure (AUC0-24) on elvitegravir clearance. Simulations confirmed that a reduced elvitegravir dose of 85 mg co-administered with cobicistat and atazanavir produces a concentration-time course comparable to the standard regimen without atazanavir. Conclusions Elvitegravir and cobicistat pharmacokinetic variability appears to be mainly explained by drug-drug interactions that may be encountered in routine clinical practice. In these cases, therapeutic drug monitoring and surveillance for potential toxicities would be justified.
Published: 2021

8. Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

Author: Hatleberg, Camilla I., Ryom, Lene, El?Sadr, Wafaa, Mocroft, Amanda, Reiss, Peter, De Wit, Stephane, Dabis, Francois, Pradier, Christian, Monforte, Antonella D'Arminio, Kovari, Helen, Law, Matthew, Lundgren, Jens D., Sabin, Caroline A., Calvo, G, Bonnet, F, Kirk, O, Morfeldt, L, Weber, R, Lind?Thomsen, A, Brandt, R Salbøl, Hillebreght, M, Zaheri, S, Wit, Fwnm, Scherrer, A, Schöni?Affolter, F, Rickenbach, M, Tavelli, A, Fanti, I, Leleux, O, Mourali, J, Le Marec, F, Boerg, E, Thulin, E, Sundström, A, Bartsch, G, Thompsen, G, Necsoi, C, Delforge, M, Fontas, E, Caissotti, C, Mateu, S, Torres, F, Petoumenos, K, Blance, A, Huang, R, Puhr, R, Laut, K, Kristensen, D, Phillips, An, Kamara, Da, Smith, Cj, Brandt, Rs, Raben, D, Matthews, C, Bojesen, A, Grevsen, Al, Powderly, B, Shortman, N, Moecklinghoff, C, Reilly, G, Franquet, X, Smit, C, Ross, M, Fux, Ca, Morlat, P, Friis?Møller, N, Kowalska, J, Bohlius, J, Bower, M, Fätkenheuer, G, Grulich, A, Sjøl, A, Meidahl, P, Iversen, Js, Hillebregt, M, Prins, Jm, Kuijpers, Tw, Scherpbier, Hj, Meer, Jtm, Godfried, Mh, Poll, T, Nellen, Fjb, Geerlings, Se, Vugt, M, Pajkrt, D, Bos, Jc, Wiersinga, Wj, Valk, M, Goorhuis, A, Hovius, Jw, Eden, J, Henderiks, A, Hes, Amh, Mutschelknauss, M, Nobel, He, Pijnappel, Fjj, Jurriaans, S, Back, Nkt, Zaaijer, Hl, Berkhout, B, Cornelissen, Mte, Schinkel, Cj, Thomas, Xv, Ziekenhuis, A De Ruyter, Berge, M, Stegeman, A, Baas, S, De Looff, L Hage, Ziekenhuis, C, Pronk, Mjh, Ammerlaan, Hsm, Munnik, E, Tjhie, J, Wegdam, Mca, Deiman, B, Scharnhorst, V, Weijsenfeld, Am, Ende, Me, Gorp, Ecm, Schurink, Cam, Nouwen, Jl, Verbon, A, Rijnders, Bja, Bax, Hi, Feltz, M, Bassant, N, Beek, Jea, Vriesde, M, Zonneveld, Lm, Oude?Lubbers, A, Berg?Cameron, Hj, Bruinsma?Broekman, Fb, Groot, J, Man, M Zeeuw?De, Boucher, Cab, Koopmans, Mpg, Kampen, Jja, Pas, Sd, Driessen, Gja, Rossum, Amc, Knaap, Lc, Flevoziekenhuis, E, Branger, J, Rijkeboer?Mes, A, Schippers, Ef, Ijperen, Jm, Geilings, J, Hut, G, Franck, Pfh, Eeden, A, Brokking, W, Groot, M, Elsenburg, Ljm, Damen, M, Isala, Is, Groeneveld, Php, Bouwhuis, Jw, Berg, Jf, Hulzen, Agw, Bliek, Gl, Bor, Pcj, Bloembergen, P, Wolfhagen, Mjhm, Ruijs, Gjhm, Kroon, Fp, Boer, Mgj, Bauer, Mp, Jolink, H, Vollaard, Am, Dorama, W, Holten, N, Claas, Ecj, Wessels, E, Den Hollander, Jg, Pogany, K, Roukens, A, Kastelijns, M, Smit, Jv, Smit, E, Struik?Kalkman, D, Tearno, C, Bezemer, M, Niekerk, T, Pontesilli, O, Lowe, Sh, Lashof, Aml Oude, Posthouwer, D, Ackens, Rp, Schippers, J, Vergoossen, R, Weijenberg?Maes, B, Loo, Ihm, Havenith, Tra, Leyten, Ems, Gelinck, Lbs, Hartingsveld, A, Meerkerk, C, Wildenbeest, Gs, Mutsaers, Jaem, Jansen, Cl, Mulder, Jw, Vrouenraets, Sme, Lauw, Fn, Broekhuizen, Mc, Paap, H, Vlasblom, Dj, Smits, Phm, Weijer, S, Moussaoui, R El, Bosma, As, Vonderen, Mga, Houte, Dpf, Kampschreur, Lm, Dijkstra, K, Faber, S, Weel, J, Kootstra, Gj, Delsing, Ce, De Plas, M Burg?Van, Heins, H, Lucas, E, Kortmann, W, Twillert¤, G, Stuart, Jwt Cohen, Diederen, Bmw, Pronk, D, Truijen?Oud, Fa, Reijden, Wa, Jansen, R, Brinkman¤, K, Berk, Gel, Blok, Wl, Frissen, Phj, Lettinga, Kd, Schouten, Wem, Veenstra, J, Brouwer, Cj, Geerders, Gf, Hoeksema, K, Kleene, Mj, Meché, Ib, Spelbrink, M, Sulman, H, Toonen, Ajm, Wijnands, S, Kwa, D, Witte, E, Koopmans, Pp, Keuter, M, Ven, Ajam, Hofstede, Hjm, Dofferhoff, Asm, Crevel, R, Albers, M, Bosch, Mew, Grintjes?Huisman, Kjt, Zomer, Bj, Stelma, Ff, Rahamat?Langendoen, J, Burger, D, Richter, C, Gisolf, Eh, Hassing, Rj, Beest, G, Van Bentum, Phm, Langebeek, N, Tiemessen, R, Swanink, Cma, Lelyveld, Sfl, Soetekouw, R, Hulshoff, N, Prijt, Lmm, Swaluw, J, Bermon, N, Herpers, Bl, Veenendaal, D, Verhagen, Dwm, Wijk, M, Brouwer, Ae, Kuipers, M, Santegoets, Rmwj, Ven, B, Marcelis, Jh, Buiting, Agm, Kabel, Pj, Bierman, Wfw, Scholvinck, H, Wilting, Kr, Stienstra, Y, Meulen, Pa, Weerd, Da, Ludwig?Roukema, J, Niesters, Hgm, Riezebos?Brilman, A, Leer?Buter, Cc, Knoester, M, Hoepelman, Aim, Mudrikova, T, Ellerbroek, Pm, Oosterheert, Jj, Arends, Je, Barth, Re, Wassenberg, Mwm, Schadd, Em, Elst?Laurijssen, Dhm, Oers?Hazelzet, Eeb, Vervoort, S, Berkel, M, Schuurman, R, Verduyn?Lunel, F, Wensing, Amj, Peters, Ejg, Agtmael, Ma, Bomers, M, Vocht, J, Heitmuller, M, Laan, Lm, Pettersson, Am, Ang, Cw, Geelen, Spm, Wolfs, Tfw, Bont, Lj, Bezemer, Do, Sighem, Ai, Boender, Ts, Jong, A, Bergsma, D, Hoekstra, P, Lang, A, Grivell, S, Jansen, A, Rademaker, Mj, Raethke, M, Meijering, R, Schnörr, S, Groot, L, Akker, M, Bakker, Y, Claessen, E, Berkaoui, A El, Koops, J, Kruijne, E, Lodewijk, C, Munjishvili, L, Peeck, B, Ree, C, Regtop, R, Ruijs, Y, Rutkens, T, Sande, L, Schoorl, M, Timmerman, A, Tuijn, E, Veenenberg, L, Vliet, S, Wisse, A, Woudstra, T, Tuk, B, Dupon, M, Gaborieau, V, Lacoste, D, Malvy, D, Mercié, P, Neau, D, Pellegrin, Jl, Tchamgoué, S, Lazaro, E, Cazanave, C, Vandenhende, M, Vareil, Mo, Gérard, Y, Blanco, P, Bouchet, S, Breilh, D, Fleury, H, Pellegrin, I, Chêne, G, Thiébaut, R, Wittkop, L, Lawson?Ayayi, S, Gimbert, A, Desjardin, S, Lacaze?Buzy, L, Petrov?Sanchez, V, André, K, Bernard, N, Caubet, O, Caunegre, L, Chossat, I, Courtault, C, Dauchy, Fa, Dondia, D, Duffau, P, Dutronc, H, Farbos, S, Faure, I, Ferrand, H, Gerard, Y, Greib, C, Hessamfar, M, Imbert, Y, Lataste, P, Marie, J, Mechain, M, Monlun, E, Ochoa, A, Pistone, T, Raymond, I, Receveur, Mc, Rispal, P, Sorin, L, Valette, C, Vandenhende, Ma, Viallard, Jf, Wille, H, Wirth, G, Lafon, Me, Trimoulet, P, Bellecave, P, Tumiotto, C, Haramburu, F, Miremeont?Salamé, G, Blaizeau, Mj, Decoin, M, Hannapier, C, Pougetoux, E Lenaud Et A., Delveaux, S, D' Ivernois, C, Diarra, F, Uwamaliya?Nziyumvira, B, Palmer, G, Conte, V, Sapparrart, V, Moore, R, Edwards, S, Hoy, J, Watson, K, Roth, N, Lau, H, Bloch, M, Baker, D, Carr, A, Cooper, D, O'Sullivan, M, Nolan, D, Guelfi, G, Domingo, P, Sambeat, Ma, Gatell, J, Del Cacho, E, Cadafalch, J, Fuster, M, Codina, C, Sirera, G, Vaqué, A, Clumeck, N, Gennotte, Af, Gerard, M, Kabeya, K, Konopnicki, D, Libois, A, Martin, C, Payen, Mc, Semaille, P, Laethem, Y, Neaton, J, Krum, E, Thompson, G, Luskin?Hawk, R, Telzak, E, Abrams, Di, Cohn, D, Markowitz, N, Arduino, R, Mushatt, D, Friedland, G, Perez, G, Tedaldi, E, Fisher, E, Gordin, F, Crane, Lr, Sampson, J, Baxter, J, Gazzard, B, Horban, A, Karpov, I, Losso, M, Pedersen, C, Ristola, M, Phillips, A, Rockstroh, J, Peters, L, Fischer, Ah, Laut, K Grønborg, Larsen, Jf, Podlekareva, D, Cozzi?Lepri, A, Shepherd, L, Schultze, A, Amele, S, Kundro, M, Schmied, B, Vassilenko, A, Mitsura, Vm, Paduto, D, Florence, E, Vandekerckhove, L, Hadziosmanovic, V, Begovac, J, Machala, L, Jilich, D, Kronborg, G, Benfield, T, Gerstoft, J, Katzenstein, T, Møller, Nf, Ostergaard, L, Wiese, L, Nielsen, Ln, Zilmer, K, Aho, I, Viard, J?P, Girard, P?M, Duvivier, C, Degen, O, Stellbrink, Hj, Stefan, C, Bogner, J, Chkhartishvili, N, Gargalianos, P, Szlávik, J, Gottfredsson, M, Mulcahy, F, Yust, I, Turner, D, Burke, M, Shahar, E, Hassoun, G, Elinav, H, Haouzi, M, Elbirt, D, Sthoeger, Zm, Esposito, R, Mazeu, I, Mussini, C, Mazzotta, F, Gabbuti, A, Vullo, V, Lichtner, M, Zaccarelli, M, Antinori, A, Acinapura, R, Plazzi, M, Lazzarin, A, Castagna, A, Gianotti, N, Galli, M, Ridolfo, A, Rozentale, B, Uzdaviniene, V, Staub, T, Ormaasen, V, Maeland, A, Bruun, J, Knysz, B, Gasiorowski, J, Inglot, M, Bakowska, E, Flisiak, R, Grzeszczuk, A, Parczewski, M, Maciejewska, K, Aksak?Was, B, Beniowski, M, Mularska, E, Smiatacz, T, Gensing, M, Jablonowska, E, Malolepsza, E, Wojcik, K, Mozer?Lisewska, I, Caldeira, L, Radoi, R, Panteleev, A, Yakovlev, A, Trofimora, T, Khromova, I, Kuzovatova, E, Borodulina, E, Vdoushkina, E, Jevtovic, D, Tomazic, J, Gatell, Jm, Miró, Jm, Moreno, S, Rodriguez, Jm, Clotet, B, Jou, A, Paredes, R, Tural, C, Puig, J, Bravo, I, Gutierrez, M, Mateo, G, Laporte, Jm, Falconer, K, Thalme, A, Sonnerborg, A, Blaxhult, A, Flamholc, L, Cavassini, M, Calmy, A, Furrer, H, Schmid, P, Kuznetsova, A, Kyselyova, G, Sluzhynska, M, Johnson, Am, Simons, E, Johnson, Ma, Orkin, C, Weber, J, Scullard, G, Clarke, A, Leen, C, Thulin, G, Åkerlund, B, Koppel, K, Karlsson, A, Håkangård, C, Castelli, F, Cauda, R, Di Perri, G, Iardino, R, Ippolito, G, Marchetti, Gc, Perno, Cf, Schloesser, F, Viale, P, Ceccherini?Silberstein, F, Girardi, E, Lo Caputo, S, Puoti, M, Andreoni, M, Ammassari, A, Balotta, C, Bandera, A, Bonfanti, P, Bonora, S, Borderi, M, Calcagno, A, Calza, L, Capobianchi, Mr, Cingolani, A, Cinque, P, De Luca, A, Di Biagio, A, Gori, A, Guaraldi, G, Lapadula, G, Madeddu, G, Maggiolo, F, Marchetti, G, Marcotullio, S, Monno, L, Nozza, S, Roldan, E Quiros, Rossotti, R, Rusconi, S, Santoro, Mm, Saracino, A, Galli, L, Lorenzini, P, Rodano, A, Shanyinde, M, Carletti, F, Carrara, S, Di Caro, A, Graziano, S, Petrone, F, Prota, G, Quartu, S, Truffa, S, Giacometti, A, Costantini, A, Barocci, V, Angarano, G, Santoro, C, Suardi, C, Donati, V, Verucchi, G, Minardi, C, Quirino, T, Abeli, C, Manconi, Pe, Piano, P, Cacopardo, B, Celesia, B, Vecchiet, J, Falasca, K, Pan, A, Lorenzotti, S, Sighinolfi, L, Segala, D, Vichi, F, Cassola, G, Viscoli, C, Alessandrini, A, Bobbio, N, Mazzarello, G, Mastroianni, C, Belvisi, V, Caramma, I, Chiodera, A, Milini, P, Rizzardini, G, Moioli, Mc, Piolini, R, Ridolfo, Al, Salpietro, S, Tincati, C, Puzzolante, C, Abrescia, N, Chirianni, A, Borgia, G, Orlando, R, Bonadies, G, Di Martino, F, Gentile, I, Maddaloni, L, Cattelan, Am, Marinello, S, Cascio, A, Colomba, C, Baldelli, F, Schiaroli, E, Parruti, G, Sozio, F, Magnani, G, Ursitti, Ma, Cristaudo, A, Baldin, G, Capozzi, M, Cicalini, S, Sulekova, L Fontanelli, Iaiani, G, Latini, A, Mastrorosa, I, Plazzi, Mm, Savinelli, S, Vergori, A, Cecchetto, M, Viviani, F, Bagella, P, Rossetti, B, Franco, A, Del Vecchio, R Fontana, Francisci, D, Di Giuli, C, Caramello, P, Orofino, Gc, Sciandra, M, Bassetti, M, Londero, A, Pellizzer, G, Manfrin, V, Starnini, G, Ialungo, A, Dollet, K, Dellamonica, P, Bernard, E, Courjon, J, Cua, E, De Salvador?Guillouet, F, Durant, J, Etienne, C, Ferrando, S, Mondain?Miton, V, Naqvi, A, Perbost, I, Pillet, S, Prouvost?Keller, B, Pugliese, P, Rio, V, Risso, K, Roger, Pm, Aubert, V, Battegay, M, Bernasconi, E, Böni, J, Braun, Dl, Bucher, Hc, Ciuffi, A, Dollenmaier, G, Egger, M, Elzi, L, Fehr, J, Fellay, J, Günthard, Hf, Haerry, D, Hasse, B, Hirsch, Hh, Hoffmann, M, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, Rd, Ledergerber, B, Martinetti, G, De Tejada, B Martinez, Marzolini, C, Metzner, Kj, Müller, N, Nicca, D, Pantaleo, G, Paioni, P, Rauch, A, Rudin, C, Scherrer, Au, Speck, R, Stöckle, M, Tarr, P, Trkola, A, Vernazza, P, Wandeler, G, and Yerly, S
Subjects: Medical care -- Utilization, Cardiovascular system -- Surgery, Sex factors in disease -- Analysis, HIV patients -- Statistics -- Care and treatment -- Demographic aspects, Health
Abstract: : Introduction: There is paucity of data related to potential gender differences in the use of interventions to prevent and treat cardiovascular disease (CVD) among HIV‐positive individuals. We investigated whether such differences exist in the observational D:A:D cohort study. Methods: Participants were followed from study enrolment until the earliest of death, six months after last visit or February 1, 2015. Initiation of CVD interventions [lipid‐lowering drugs (LLDs), angiotensin‐converting enzyme inhibitors (ACEIs), anti‐hypertensives, invasive cardiovascular procedures (ICPs) were investigated and Poisson regression models calculated whether rates were lower among women than men, adjusting for potential confounders. Results: Women (n = 12,955) were generally at lower CVD risk than men (n = 36,094). Overall, initiation rates of CVD interventions were lower in women than men; LLDs: incidence rate 1.28 [1.21, 1.35] vs. 2.40 [2.34, 2.46]; ACEIs: 0.88 [0.82, 0.93] vs. 1.43 [1.39, 1.48]; anti‐hypertensives: 1.40 [1.33, 1.47] vs. 1.72 [1.68, 1.77] and ICPs: 0.08 [0.06, 0.10] vs. 0.30 [0.28, 0.32], and this was also true for most CVD interventions when exclusively considering periods of follow‐up for which individuals were at high CVD risk. In fully adjusted models, women were less likely to receive CVD interventions than men (LLDs: relative rate 0.83 [0.78, 0.88]; ACEIs: 0.93 [0.86, 1.01]; ICPs: 0.54 [0.43, 0.68]), except for the receipt of anti‐hypertensives (1.17 [1.10, 1.25]). Conclusion: The use of most CVD interventions was lower among women than men. Interventions are needed to ensure that all HIV‐positive persons, particularly women, are appropriately monitored for CVD and, if required, receive appropriate CVD interventions., Introduction HIV‐positive individuals are known to be at increased risk of cardiovascular disease (CVD) compared to the general population, partly due to an increased prevalence of some CVD risk factors, [...]
Published: 2018
Full Text: View/download PDF

9. Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection

Author: Fitzmaurice, Karen, Hurst, Jacob, Dring, Megan, Rauch, Andri, McLaren, Paul J, Günthard, Huldrych F, Gardiner, Clair, Klenerman, Paul, Courtney, Garry, Crosbie, Orla, Crowe, John, Fanning, Liam, Hegarty, John, Kelleher, Dermot, Lawlor, Emer, Lee, John, McKiernan, Susan, Murray, Frank, Norris, Suzanne, OʼFarrelly, Cliona, Thornton, Leila, Aubert, V, Battegay, M, Bernasconi, E, Böni, J, Bucher, HC, Burton-Jeangros, C, Calmy, A, Cavassini, M, Egger, M, Elzi, L, Fehr, J, Fellay, J, Furrer, H, Fux, CA, Gorgievski, M, Günthard, H, Haerry, D, Hasse, B, Hirsch, HH, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, R, Kovari, H, Ledergerber, B, Martinetti, G, Martinez de Tejada, B, Metzner, K, Müller, N, Nadal, D, Pantaleo, G, Rauch, A, Regenass, S, Rickenbach, M, Rudin, C, Schöni-Affolter, F, Schmid, P, Schultze, D, Schüpbach, J, Speck, R, Tarr, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, and Yerly, S
Published: 2015
Full Text: View/download PDF

10. Mycoplasma pneumoniae detection in children with respiratory tract infections and influence on management – a retrospective cohort study in Switzerland

Author: Dierig, A, Hirsch, HH, Decker, M-L, Bielicki, JA, Heininger, U, and Ritz, N
Abstract: Aim\ud To evaluate the frequency of Mycoplasma pneumoniae in nasopharyngeal specimens from children with respiratory tract infections (RTIs) and to detail clinical characteristics and management.\ud \ud Methods\ud The study was designed as a retrospective cohort study. All children with RTI and nucleic acid amplification testing from nasopharyngeal specimens were analysed. Clinical data were extracted from electronic health records for all M. pneumoniae‐positive cases. Stored samples of cases and a random selection of matched controls were retested using a M. pneumoniae‐specific nucleic acid amplification test.\ud \ud Results\ud Of 4460 children, 70 (1.6%) were positive for M. pneumoniae with a median age of 6.4 (IQR: 2.7–9.7). M. pneumoniae was the only organism identified in 50/64 (78%) cases. Macrolide treatment was prescribed in 52/65 (80%); prescription was empirical in 29/52 (56%) and targeted in 23/52 (44%) with no difference regarding patient age, oxygen requirement or duration of hospitalisation.\ud \ud Conclusion\ud The prevalence of M. pneumoniae in nasopharyngeal specimens of children with RTI was low. The detection of M. pneumoniae influenced antibiotic prescriptions, but the benefit of early empirical versus targeted treatment remains unclear.
Published: 2020

11. Using longitudinally sampled viral nucleotide sequences to characterize the drivers of HIV‐1 transmission.

Author: Reichmuth, ML, Chaudron, SE, Bachmann, N, Nguyen, H, Böni, J, Metzner, KJ, Perreau, M, Klimkait, T, Yerly, S, Hirsch, HH, Hauser, C, Ramette, A, Vernazza, P, Cavassini, M, Bernasconi, E, Günthard, HF, Kusejko, K, and Kouyos, RD
Subjects: HIV infections, SEQUENCE analysis, CONFIDENCE intervals, VIRAL load, SYPHILIS, ANTIRETROVIRAL agents, NUCLEOTIDES, INFECTIOUS disease transmission, VIROLOGY, ODDS ratio, MOLECULAR epidemiology, HIV, LONGITUDINAL method
Abstract: Objectives: Understanding the drivers of HIV‐1 transmission is of importance for curbing the ongoing epidemic. Phylogenetic methods based on single viral sequences allow us to assess whether two individuals are part of the same viral outbreak, but cannot on their own assess who potentially transmitted the virus. We developed and assessed a molecular epidemiology method with the main aim to screen cohort studies for and to characterize individuals who are 'potential HIV‐1 transmitters', in order to understand the drivers of HIV‐1 transmission. Methods: We developed and validated a molecular epidemiology approach using longitudinally sampled viral Sanger sequences to characterize potential HIV‐1 transmitters in the Swiss HIV Cohort Study. Results: Our method was able to identify 279 potential HIV‐1 transmitters and allowed us to determine the main epidemiological and virological drivers of transmission. We found that the directionality of transmission was consistent with infection times for 72.9% of 85 potential HIV‐1 transmissions with accurate infection date estimates. Being a potential HIV‐1 transmitter was associated with risk factors including viral load [adjusted odds ratiomultivariable (95% confidence interval): 1.86 (1.49–2.32)], syphilis coinfection [1.52 (1.06–2.19)], and recreational drug use [1.45 (1.06–1.98)]. By contrast for the potential HIV‐1 recipients, this association was weaker or even absent [1.18 (0.82–1.72), 0.89 (0.52–1.55) and 1.53 (0.98–2.39), respectively], indicating that inferred directionality of transmission is useful at the population level. Conclusions: Our results indicate that longitudinally sampled Sanger sequences do not provide sufficient information to identify transmitters with high certainty at the individual level, but that they allow the drivers of transmission at the population level to be characterized. [ABSTRACT FROM AUTHOR]
Published: 2021
Full Text: View/download PDF

12. Clostridium difficile infection is associated with graft loss in solid organ transplant recipients

Author: Cusini, A, Béguelin, C, Stampf, S, Boggian, K, Garzoni, C, Koller, M, Manuel, O, Meylan, P, Mueller, NJ, Hirsch, HH, Weisser, M, Berger, C, van Delden, C, Achermann, R, Amico, P, Aubert, JD, Banz, V, Beldi, G, Benden, C, Binet, I, Bochud, PY, Bucher, H, Bühler, L, Carell, T, Catana, E, Chalandon, Y, de Geest, S, de Rougemont, O, Dickenmann, M, Duchosal, M, Elkrief, L, Fehr, T, Ferrari-Lacraz, S, Gasche Soccal, P, Gaudet, C, Giostra, E, Golshayan, D, Hadaya, K, Halter, J, Heim, D, Hess, C, Hillinger, S, Hofbauer, G, Huynh-Do, U, Immer, F, Klaghofer, R, Laesser, B, Lehmann, R, Lovis, C, Marti, HP, Martin, PY, Mohacsi, P, Morel, P, Mueller, U, Mueller-McKenna, H, Müller, A, Müller, T, Müllhaupt, B, Nadal, D, Pascual, M, Passweg, J, Rick, J, Roosnek, E, Rosselet, A, Rothlin, S, Ruschitzka, F, Schanz, U, Schaub, S, Schnyder, A, Seiler, C, Steiger, J, Stirnimann, G, Toso, C, Venetz, JP, Villard, J, Wick, M, Wilhelm, M, Yerly, P, Gasche-Soccal, Paola Marina Alessandra, University of Zurich, and van Delden, C
Subjects: Graft Rejection, Male, genetic structures, 2747 Transplantation, 10265 Clinic for Endocrinology and Diabetology, 030230 surgery, 10234 Clinic for Infectious Diseases, 0302 clinical medicine, Postoperative Complications, Risk Factors, Medicine, 2736 Pharmacology (medical), Immunology and Allergy, Pharmacology (medical), 030212 general & internal medicine, Prospective Studies, 610 Medicine & health, Prospective cohort study, ddc:616, Incidence, Hazard ratio, Graft Survival, Clostridium difficile, Middle Aged, Prognosis, Anti-Bacterial Agents, Diarrhea, 10209 Clinic for Cardiology, 2723 Immunology and Allergy, Female, medicine.symptom, 10178 Clinic for Pneumology, Switzerland, Cohort study, medicine.medical_specialty, 03 medical and health sciences, Internal medicine, Humans, Transplantation, business.industry, Clostridioides difficile, Case-control study, Organ Transplantation, Confidence interval, Transplant Recipients, 10036 Medical Clinic, Case-Control Studies, Clostridium Infections, business, Follow-Up Studies
Abstract: © 2018 The American Society of Transplantation and the American Society of Transplant Surgeons Clostridium difficile infection (CDI) is a leading cause of infectious diarrhea in solid organ transplant recipients (SOT). We aimed to assess incidence, risk factors, and outcome of CDI within the Swiss Transplant Cohort Study (STCS). We performed a case-control study of SOT recipients in the STCS diagnosed with CDI between May 2008 and August 2013. We matched 2 control subjects per case by age at transplantation, sex, and transplanted organ. A multivariable analysis was performed using conditional logistic regression to identify risk factors and evaluate outcome of CDI. Two thousand one hundred fifty-eight SOT recipients, comprising 87 cases of CDI and 174 matched controls were included. The overall CDI rate per 10 000 patient days was 0.47 (95% confidence interval ([CI] 0.38-0.58), with the highest rate in lung (1.48, 95% CI 0.93-2.24). In multivariable analysis, proven infections (hazard ratio [HR] 2.82, 95% CI 1.29-6.19) and antibiotic treatments (HR 4.51, 95% CI 2.03-10.0) during the preceding 3 months were independently associated with the development of CDI. Despite mild clinical presentations, recipients acquiring CDI posttransplantation had an increased risk of graft loss (HR 2.24, 95% CI 1.15-4.37; P =.02). These findings may help to improve the management of SOT recipients. ispartof: American Journal of Transplantation vol:18 issue:7 pages:1745-1754 ispartof: location:United States status: published
Published: 2017

13. Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey

Author: Navarro D, San-Juan R, Manuel O, Giménez E, Fernández-Ruiz M, Hirsch HH, Grossi PA, Aguado JM, and ESGICH CMV Survey Study Group O
Published: 2017

14. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

Author: Steering, D, Powderly, B, Shortman, N, Moecklinghoff, C, Reilly, G, Franquet, X, Ryom, L, Hatleberg, Ci, Sabin, Ca, Kamara, D, Smith, C, Phillips, A, Mocroft, A, Bojesen, A, Grevsen, A, Matthews, C, Raben, D, Lundgren, Jd, Brandt, Rs, Rickenbach, M, Fanti, I, Hillebreght, M, Zaheri, S, Gras, L, Pernot, E, Mourabi, J, Sundström, A, Delforge, M, Fontas, E, Torres, F, Mcmanus, H, Wright, S, Kristensen, D, Sjøl, A, Meidahl, P, Helweg-Larsen, J, Schmidt Iversen, J, Kirk, O, Reiss, P, Smit, C, Ross, M, Fux, Ca, Morlat, P, Moranne, O, Kamara, Da, Weber, R, Pradier, C, Friis-Møller, N, Kowalska, J, Sabin, C, Law, M, d'Arminio Monforte, A, Dabis, F, Bruyand, M, Bonnet, F, Bower, M, Fätkenheuer, G, Donald, A, Grulich, A, Prins, Jm, Kuijpers, Tw, Scherpbier, Hj, van der Meer JT, Wit, Fw, Godfried, Mh, van der Poll, T, Nellen, Fj, Geerlings, Se, van Vugt, M, Pajkrt, D, Bos, Jc, Wiersinga, Wj, van der Valk, M, Goorhuis, A, Hovius, Jw, van Eden, J, Henderiks, A, van Hes AM, Mutschelknauss, M, Nobel, He, Pijnappel, Fj, Westerman, Am, Jurriaans, S, Back, Nk, Zaaijer, Hl, Berkhout, B, Cornelissen, Mt, Schinkel, Cj, Thomas, Xv, De Ruyter Ziekenhuis, A, van den Berge, M, Stegeman, A, Baas, S, de Looff, L, Versteeg, D, Pronk, Mj, Ammerlaan, Hs, Korsten-Vorstermans, Em, de Munnik ES, Jansz, Ar, Tjhie, J, Wegdam, Mc, Deiman, B, Scharnhorst, V, Kinderziekenhuis, E, van der Plas, A, Weijsenfeld, Am, van der Ende ME, de Vries-Sluijs TE, van Gorp EC, Schurink, Ca, Nouwen, Jl, Verbon, A, Rijnders, Bj, Bax, Hi, Hassing, Rj, van der Feltz, M, Bassant, N, van Beek JE, Vriesde, M, van Zonneveld LM, de Oude-Lubbers, A, van den Berg-Cameron HJ, Bruinsma-Broekman, Fb, de Groot, J, de Man de, Z, Broekhoven-Kruijne, Mj, Schutten, M, Osterhaus, Ad, Boucher, Ca, Driessen, Gj, van Rossum AM, van der Knaap LC, Visser, E, Branger, J, Duijf-van de Ven CJ, Haag, D, Schippers, Ef, van Nieuwkoop, C, Brimicombe, Rw, van IJperen, M, van der Hut, G, Franck, Pf, van Eeden, A, Brokking, W, Groot, M, Damen, M, Kwa, Is, Groeneveld, Ph, Bouwhuis, Jw, van den Berg JF, van Hulzen AG, van der Bliek GL, Bor, Pc, Bloembergen, P, Wolfhagen, Mj, Ruijs, Gj, Gasthuis, K, van Lelyveld SF, Soetekouw, R, Hulshoff, N, van der Prijt LM, Schoemaker, M, Bermon, N, van der Reijden WA, Jansen, R, Herpers, Bl, Veenendaal, D, Kroon, Fp, Arend, Sm, de Boer MG, Bauer, Mp, Jolink, H, Vollaard, Am, Dorama, W, Moons, C, Claas, Ec, Kroes, Ac, den Hollander JG, Pogany, K, Kastelijns, M, Smit, Jv, Smit, E, Bezemer, M, van Niekerk, T, Pontesilli, O, Lowe, Sh, Oude Lashof, A, Posthouwer, D, Ackens, Rp, Schippers, J, Vergoossen, R, Weijenberg Maes, B, Savelkoul, Ph, Loo, Ih, Zuiderzee, Mc, Weijer, S, El Moussaoui, R, Heitmuller, M, Kortmann, W, van Twillert, G, Cohen Stuart JW, Diederen, Bm, Pronk, D, van Truijen-Oud FA, van der Reijden, W, Leyten, Em, Gelinck, Lb, van Hartingsveld, A, Meerkerk, C, Wildenbeest, Gs, Mutsaers, Ja, Jansen, Cl, van Vonderen MG, van Houte DP, Dijkstra, K, Faber, S, Weel, J, Kootstra, Gj, Delsing, Ce, van der Burgvan de Plas, M, Heins, H, Lucas, E, Brinkman, K, Frissen, Ph, Blok, Wl, Schouten, We, Bosma, As, Brouwer, Cj, Geerders, Gf, Hoeksema, K, Kleene, Mj, van der Meché IB, Toonen, Aj, Wijnands, S, van Ogtrop ML, Koopmans, Pp, Keuter, M, van der Ven AJ, ter Hofstede HJ, Dofferhoff, As, van Crevel, R, Albers, M, Bosch, Me, Grintjes-Huisman, Kj, Zomer, Bj, Stelma, Ff, Burger, D, Richter, C, van der Berg JP, Gisolf, Eh, Beest, G, van Bentum PH, Langebeek, N, Tiemessen, R, Swanink, Cm, Veenstra, J, Lettinga, Kd, Spelbrink, M, Sulman, H, Witte, E, Peerbooms, Pg, Mulder, Jw, Vrouenraets, Sm, Lauw, Fn, van Broekhuizen MC, Paap, H, Vlasblom, Dj, Oudmaijer Sanders, E, Smits, Ph, Rosingh, Aw, Verhagen, Dw, Geilings, J, van Kasteren ME, Brouwer, Ae, de Kruijf-van de Wiel BA, Kuipers, M, Santegoets, Rm, van der Ven, B, Marcelis, Jh, Buiting, Ag, Kabel, Pj, Bierman, Wf, Sprenger, Hg, Scholvinck, Eh, van Assen, S, Wilting, Kr, Stienstra, Y, de Groot-de Jonge, H, van der Meulen PA, de Weerd DA, Niesters, Hg, Riezebos-Brilman, A, van Leer-Buter CC, Hoepelman, Ai, Schneider, Mm, Mudrikova, T, Ellerbroek, Pm, Oosterheert, Jj, Arends, Je, Barth, Re, Wassenberg, Mw, van Elst-Laurijssen DH, Laan, Lm, van Oers-Hazelzet EE, Patist, J, Vervoort, S, Nieuwenhuis, He, Frauenfelder, R, Schuurman, R, Verduyn-Lunel, F, Wensing, Am, Peters, Ej, van Agtmael MA, Perenboom, Rm, Bomers, M, de Vocht, J, Elsenburg, Lj, Pettersson, Am, Vandenbroucke-Grauls, Cm, Ang, Cw, Geelen, Sp, Wolfs, Tf, Bont, Lj, Nauta, N, Bezemer, Do, van Sighem AI, Hillebregt, M, Kimmel, V, Tong, Y, Lascaris, B, van den Boogaard, R, Hoekstra, P, de Lang, A, Berkhout, M, Grivell, S, Jansen, A, de Groot, L, van den Akker, M, Bergsma, D, Lodewijk, C, Meijering, R, Peeck, B, Raethke, M, Ree, C, Regtop, R, Ruijs, Y, Schoorl, M, Tuijn, E, Veenenberg, L, Woudstra, T, Bakker, Y, de Jong, A, Broekhoven, M, Claessen, E, Rademaker, Mj, Munjishvili, L, Kruijne, E, Tuk, B, Bouchet, S, Breilh, D, Chêne, G, Dupon, M, Fleury, H, Gaborieau, V, Lacoste, D, Malvy, D, Mercié, P, Neau, D, Pellegrin, I, Pellegrin, Jl, Tchamgoué, S, Fagard, C, Lawson-Ayayi, S, Richert, L, Thiébaut, R, Wittkop, L, André, K, Bernard, N, Caunègre, L, Cazanave, C, Ceccaldi, J, Chossat, I, Courtault, C, Dauchy, Fa, De Witte, S, Dondia, D, Dupont, A, Duffau, P, Dutronc, H, Farbos, S, Faure, I, Gerard, Y, Greib, C, Hessamfar-Joseph, M, Imbert, Y, Lataste, P, Lazaro, E, Marie, J, Mechain, M, Meraud, Jp, Monlun, E, Ochoa, A, Pillot-Debelleix, M, Pistone, T, Raymond, I, Receveur, Mc, Rispal, P, Sorin, L, Valette, C, Vandenhende, Ma, Vareil, Mo, Viallard, Jf, Wille, H, Wirth, G, Moreau, Jf, Lafon, Me, Reigadas, S, Trimoulet, P, Haramburu, F, Miremont-Salamé, G, Blaizeau, Mj, Crespel, I, Decoin, M, Delveaux, S, Diarra, F, D'Ivernois, C, Hanappier, C, Leleux, O, Le Marec, F, Lenaud, E, Mourali, J, Pougetoux, A, Uwamaliya-Nziyumvira, B, Tsaranazy, A, Valdes, A, Conte, V, Louis, I, Palmer, G, Sapparrart, V, Touchard, D, Petoumenos, K, Bendall, C, Moore, R, Edwards, S, Hoy, J, Watson, K, Roth, N, Nicholson, J, Bloch, M, Franic, T, Baker, D, Vale, R, Carr, A, Cooper, D, Chuah, J, Ngieng, M, Nolan, D, Skett, J, Calvo, G, Mateu, S, Domingo, P, Sambeat, Ma, Gatell, J, Del Cacho, E, Cadafalch, J, Fuster, M, Codina, C, Sirera, G, Vaqué, A, De Wit, S, Clumeck, N, Necsoi, C, Gennotte, Af, Gerard, M, Kabeya, K, Konopnicki, D, Libois, A, Martin, C, Payen, Mc, Semaille, P, Van, Y, Neaton, J, Bartsch, G, El-Sadr, Wm, Krum, E, Thompson, G, Wentworth, D, Luskin-Hawk, R, Telzak, E, Abrams, Di, Cohn, D, Markowitz, N, Arduino, R, Mushatt, D, Friedland, G, Perez, G, Tedaldi, E, Fisher, E, Gordin, F, Crane, Lr, Sampson, J, Baxter, J, Losso, M, Kundro, M, Vetter, N, Zangerle, R, Karpov, I, Vassilenko, A, Mitsura, Vm, Paduto, D, Florence, E, Vandekerckhove, L, Hadziosmanovic, V, Kostov, K, Begovac, J, Machala, L, Jilich, D, Sedlacek, D, Kronborg, G, Benfield, T, Gerstoft, J, Katzenstein, T, Hansen, Ab, Pedersen, C, Møller, Nf, Ostergaard, L, Dragsted, Ub, Nielsen, Ln, Zilmer, K, Smidt, J, Ristola, M, Aho, I, Katlama, C, Viard, Jp, Girard, Pm, Cotte, L, Duvivier, C, Rockstroh, J, Schmidt, R, van Lunzen, J, Degen, O, Stellbrink, Hj, Stefan, C, Bogner, J, Chkhartishvili, N, Kosmidis, J, Gargalianos, P, Xylomenos, G, Lourida, P, Sambatakou, H, Banhegyi, D, Gottfredsson, M, Mulcahy, F, Yust, I, Turner, D, Burke, M, Shahar, E, Hassoun, G, Elinav, H, Haouzi, M, Sthoeger, Zm, D'Arminio Monforte, A, Esposito, R, Mazeu, I, Mussini, C, Mazzotta, F, Gabbuti, A, Vullo, V, Lichtner, M, Zaccarelli, M, Antinori, A, Acinapura, R, D'Offizi, G, Lazzarin, A, Castagna, A, Gianotti, N, Galli, M, Ridolfo, A, Rozentale, B, Uzdaviniene, V, Matulionyte, R, Staub, T, Hemmer, R, Ormaasen, V, Maeland, A, Bruun, J, Knysz, B, Gasiorowski, J, Inglot, M, Horban, A, Bakowska, E, Grzeszczuk, A, Flisiak, R, Parczewski, M, Pynka, M, Maciejewska, K, Beniowski, M, Mularska, E, Smiatacz, T, Gensing, M, Jablonowska, E, Malolepsza, E, Wojcik, K, Mozer-Lisewska, I, Doroana, M, Caldeira, L, Mansinho, K, Maltez, F, Radoi, R, Oprea, C, Rakhmanova, A, Trofimora, T, Khromova, I, Kuzovatova, E, Jevtovic, D, Shunnar, A, Staneková, D, Tomazic, J, Moreno, S, Rodriguez, J, Clotet, B, Jou, A, Paredes, R, Tural, C, Puig, J, Bravo, I, Gatell, Jm, Miró, Jm, Gutierrez, M, Mateo, G, Laporte, Jm, Blaxhult, A, Flamholc, L, Falconer, K, Thalme, A, Sonnerborg, A, Ledergerber, B, Cavassini, M, Calmy, A, Furrer, H, Battegay, M, Elzi, L, Schmid, P, Kravchenko, E, Chentsova, N, Frolov, V, Kutsyna, G, Baskakov, I, Servitskiy, S, Kuznetsova, A, Kyselyova, G, Gazzard, B, Johnson, Am, Simons, E, Johnson, Ma, Orkin, C, Weber, J, Scullard, G, Fisher, M, Leen, C, Lundgren, J, Grarup, J, Cozzi-Lepri, A, Thiebaut, R, Peters, L, Fischer, Ah, Grønborg Laut, K, Larsen, Jf, Podlekareva, D, Grint, D, Shepherd, L, Schultze, A, Morfeldt, L, Thulin, G, Åkerlund, B, Koppel, K, Karlsson, A, Håkangård, C, Moroni, M, Angarano, G, Armignacco, O, Castelli, F, Cauda, R, Di Perri, G, Iardino, R, Ippolito, G, Perno, Cf, von Schloesser, F, Viale, P, Ceccherini-Silberstein, F, Girardi, E, Lo Caputo, S, Puoti, M, Andreoni, M, Ammassari, A, Balotta, C, Bonfanti, P, Bonora, S, Borderi, M, Capobianchi, R, Cingolani, A, Cinque, P, De Luca, A, Di Biagio, A, Gori, A, Guaraldi, G, Lapadula, G, Madeddu, G, Maggiolo, F, Marchetti, G, Marcotullio, S, Monno, L, Quiros Roldan, E, Rusconi, S, Cicconi, P, Formenti, T, Galli, L, Lorenzini, P, Giacometti, A, Costantini, A, Santoro, C, Suardi, C, Vanino, E, Verucchi, G, Minardi, C, Quirino, T, Abeli, C, Manconi, Pe, Piano, P, Vecchiet, J, Falasca, K, Sighinolfi, L, Segala, D, Cassola, G, Viscoli, G, Alessandrini, A, Piscopo, R, Mazzarello, G, Mastroianni, C, Belvisi, V, Castelli, A, Rizzardini, G, Ridolfo, Al, Piolini, R, Salpietro, S, Carenzi, L, Moioli, Mc, Puzzolante, C, Abrescia, N, Chirianni, A, Guida, Mg, Onofrio, M, Baldelli, F, Francisci, D, Parruti, G, Ursini, T, Magnani, G, Ursitti, Ma, D'Avino, A, Gallo, L, Nicastri, E, Capozzi, M, Libertone, R, Tebano, G, Cattelan, A, Mura, Ms, Caramello, P, Orofino, Gc, Sciandra, M, Pellizzer, G, Manfrin, V, Castelli, Ap, Dollet, K, Caissotti, C, Dellamonica, P, Bernard, E, Cua, E, De Salvador-Guillouet, F, Durant, J, Ferrando, S, Dunais, B, Mondain-Miton, V, Naqvi, A, Perbost, I, Prouvost-Keller, B, Pillet, S, Pugliese, P, Risso, K, Roger, Pm, Aubert, V, Bernasconi, E, Böni, J, Bucher, Hc, Burton-Jeangros, C, Dollenmaier, G, Egger, M, Fehr, J, Fellay, J, Gorgievski, M, Günthard, H, Haerry, D, Hasse, B, Hirsch, Hh, Hoffmann, M, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, R, Kovari, H, Martinetti, G, Martinez de Tejada, B, Metzner, K, Müller, N, Nadal, D, Nicca, D, Pantaleo, G, Rauch, A, Regenass, S, Rudin, C, Schöni-Affolter, F, Schüpbach, J, Speck, R, Tarr, P, Telenti, A, Trkola, A, Vernazza, P, Yerly, S., University College of London [London] (UCL), Rigshospitalet [Copenhagen], Copenhagen University Hospital, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Bordeaux [Bordeaux], Chemical Biology, Internal Medicine, Medical Microbiology & Infectious Diseases, Pediatrics, Virology, Mocroft, A:, Lundgren, Jd, Ross, M, Fux, Ca, Reiss, P, Moranne, O, Morlat., P, Monforte, Ad, Kirk, O, Ryom, L, for the Data Collection on Adverse events of Anti-HIV Drugs (D:A:D), Study, Lazzarin, A, Castagna, A, Other departments, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Global Health, Infectious diseases, Paediatric Infectious Diseases / Rheumatology / Immunology, General Internal Medicine, Center of Experimental and Molecular Medicine, Graduate School, Medical Microbiology and Infection Prevention, Gastroenterology and Hepatology, APH - Health Behaviors & Chronic Diseases, Med Microbiol, Infect Dis & Infect Prev, MUMC+: DA MMI Staf (9), MUMC+: MA Alg Interne Geneeskunde (9), MUMC+: DA MMI Infectieserologie (9), MUMC+: DA MMI AIOS (9), RS: FHML non-thematic output, Mocroft, A, Lundgren, J, Fux, C, Morlat, P, Monforte, A, and Gori, A
Subjects: 0301 basic medicine, Male, PROTEASE INHIBITOR, Epidemiology, Infectious Diseases, Immunology, Virology, Research Support, U.S. Gov't, P.H.S, HIV Infections, SDG 3 – Goede gezondheid en welzijn, Rate ratio, THERAPY, chemistry.chemical_compound, 0302 clinical medicine, HIV, antiretroviral, kidney disease, immune system diseases, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine and Health Sciences, HIV Infection, 030212 general & internal medicine, Prospective Studies, Renal Insufficiency, Chronic, Prospective cohort study, Research Support, Non-U.S. Gov't, Antiretrovirals, virus diseases, Lopinavir, ASSOCIATION, Middle Aged, 3. Good health, Europe, Antiretrovirals, HIV, chronic kidney disease, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, NAIVE PATIENTS, CREATININE, Human, Cohort study, medicine.drug, Glomerular Filtration Rate, United State, Adult, medicine.medical_specialty, TENOFOVIR DISOPROXIL FUMARATE, RENAL-FUNCTION, Adolescent, Anti-HIV Agents, Atazanavir Sulfate, Renal function, Infectious Disease, Australia, Humans, Renal Insufficiency, Chronic, Tenofovir, United States, Young Adult, NO, 03 medical and health sciences, EFAVIRENZ, SDG 3 - Good Health and Well-being, Internal medicine, Journal Article, medicine, Creatinine, business.industry, Anti-HIV Agent, medicine.disease, 030112 virology, Atazanavir, INFECTED INDIVIDUALS, Prospective Studie, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], chemistry, RISK-FACTORS, business, chronic kidney disease, Kidney disease
Abstract: BACKGROUND: Whether or not the association between some antiretrovirals used in HIV infection and chronic kidney disease is cumulative is a controversial topic, especially in patients with initially normal renal function. In this study, we aimed to investigate the association between duration of exposure to antiretrovirals and the development of chronic kidney disease in people with initially normal renal function, as measured by estimated glomerular filtration rate (eGFR).METHODS: In this prospective international cohort study, HIV-positive adult participants (aged ≥16 years) from the D:A:D study (based in Europe, the USA, and Australia) with first eGFR greater than 90 mL/min per 1·73 m(2) were followed from baseline (first eGFR measurement after Jan 1, 2004) until the occurrence of one of the following: chronic kidney disease; last eGFR measurement; Feb 1, 2014; or final visit plus 6 months (whichever occurred first). Chronic kidney disease was defined as confirmed (>3 months apart) eGFR lower than 60 mL/min per 1·73 m(2). The primary outcome was the occurrence of chronic kidney disease. Poisson regression was used to estimate the incidence rate of chronic kidney disease associated with cumulative exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazanavir, ritonavir-boosted lopinavir, other ritonavir-boosted protease inhibitors, or abacavir.FINDINGS: Between Jan 1, 2004, and July 26, 2013, 23,905 eligible individuals from the D:A:D study were included. Participants had a median baseline eGFR of 110 mL/min per 1·73 m(2) (IQR 100-125), a median age of 39 years (33-45), and median CD4 cell count of 441 cells per mm(3) (294-628). During a median follow-up of 7·2 years (IQR 5·1-8·9), 285 (1%) of 23,905 people developed chronic kidney disease (incidence 1·76 per 1000 person-years of follow-up [95% CI 1·56-1·97]). After adjustment, we recorded a significant increase in chronic kidney disease associated with each additional year of exposure to tenofovir disoproxil fumarate (adjusted incidence rate ratio 1·14 [95% CI 1·10-1·19], pINTERPRETATION: In people with normal renal function, the annual incidence of chronic kidney disease increased for up to 6 years of exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazanavir, or ritonavir-boosted lopinavir therapy. Although the absolute number of new cases of chronic kidney disease was modest, treatment with these antiretrovirals might result in an increasing and cumulative risk of chronic kidney disease. Patients on potentially nephrotoxic antiretrovirals or at high risk of chronic kidney disease should be closely monitored.FUNDING: The Highly Active Antiretroviral Therapy Oversight Committee.
Published: 2016
Full Text: View/download PDF

15. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: An international cohort study

Author: Podlekareva Daria, N, Efsen Anne Marie, W, Schultze, A, Post Frank, A, Skrahina Alena, M, Panteleev, A, Furrer, H, Miller Robert, F, Losso, M. H, Toibaro, J, Miro Jose, M, Vassilenko, A, Girardi, Enrico, Bruyand, M, Obel, N, Lundgren Jens, D, Mocroft, A, Kirk, O, Karpov, I, Skrahina, A, Klimuk, D, Skrahin, A, Kondratenko, O, Zalutskaya, A, Bondarenko, V, Mitsura, V, Kozorez, E, Tumash, O, Suetnov, O, Paduto, D, Iljina, V, Kummik, T, Bolokadze, N, Mshvidobadze, K, Lanchava, N, Goginashvili, L, Mikiashvili, L, Bablishvili, N, Rozentale, B, Zeltina, I, Janushkevich, I, Caplinskiene, I, Caplinskas, S, Kancauskiene, Z, Podlasin, R, Wiercinska Drapalo, A, Thompson, M, Kozlowska, J, Grezesczuk, A, Bura, M, Knysz, B, Inglot, M, Garlicki, A, Loster, J, Duiculescu, D, Tetradov, S, Rakhmanova, A, Panteleeva, O, Yakovlev, A, Kozlov, A, Tyukalova, A, Vlasova, Y, Trofimov, T, Kyselyova, G, Thorsteinsson, K, Payen, Mc, Kabeya, K, Necsoi, C, Dabis, F, Morlat, P, Dupont, A, Gerard, Y, Bonnal, F, Ceccaldi, J, De Witte, S, Monlun, E, Lataste, P, Chossat, I, Sagette, M, Rickenbach, M, Elzi, L, Battegay, M, Sculier, D, Calmy, A, Cavassini, M, Bruno, A, Bernasconi, E, Hoffmann, M, Vernazza, P, Fehr, J, Weber, R, Aubert, V, Böni, J, Bucher, Hc, Burton Jeangros, C, Dollenmaier, G, Egger, M, Fellay, J, Fux, Ca, Gorgievski, M, Günthard, H, Haerry, D, Hasse, B, Hirsch, Hh, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, R, Kovari, H, Ledergerber, B, Martinetti, G, Martinez de Tejada, B, Metzner, K, Müller, N, Nadal, D, Nicca, D, Pantaleo, G, Rauch, A, Regenass, S, Rudin, C, Schöni Affolter, F, Schmid, P, Schüpbach, J, Speck, R, Tarr, P, Telenti, A, Trkola, A, Yerly, S, Miller, Rf, Vora, N, Cooke, G, Mullaney, S, Wilkins, E, George, V, Collini, P, Dockrell, D, Post, F, Campbell, L, Brum, R, Mabonga, E, Saigal, P, Kegg, S, Ainsworth, J, Waters, A, Dhar, J, Mashonganyika, L, Girardi, E, Rianda, A, Galati, V, Pinnetti, C, Tommasi, C, Lapadula, G, Di Biagio, A, Parisini, A, Carbonara, S, Angarano, G, Purgatorio, M, Matteelli, Alberto, Apostoli, A, Miro, Jm, Manzardo, C, Ligero, C, Gonzalez, J, Martinez Martinez, Ja, Sanchez, F, Knobel, H, Salvadó, M, Lopez Colomes, Jl, Martínez Lacasa, X, Cuchí, E, Falcó, V, Curran, A, Tortola, Mt, Ocaña, I, Vidal, R, Sambeat, Ma, Pomar, V, Coll, P, Pozamczer, D, Saumoy, M, Alcaide, F, Caylà, J, Moreno, A, Millet, Jp, Orcau, A, Fina, L, Romero, A, Roldan, Ll, Iribarren, Ja, Ibarguren, M, Moreno, S, González, A, Miralles, P, Aldámiz Echevarría, T, Losso, M, Gambardella, L, Macias, L, Warley, E, Tavella, S, Messina, O, Gear, O, Laplume, H, Marson, C, Contarelia, J, Michaan, M, Scapellato, P, Alessandro, D, Bartoletti, B, Palmero, D, Elias, C, Cortes, C, Crabtree, B, Gomez, Jl, Hernandez, La, and Badial, F.
Subjects: Adult, Male, 0301 basic medicine, Pediatrics, medicine.medical_specialty, Latin Americans, Tuberculosis, Anti-HIV Agents, Epidemiology, 030106 microbiology, Population, Infectious Diseases, Immunology, Virology, Antitubercular Agents, HIV Infections, Cohort Studies, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Tuberculosis, Multidrug-Resistant, medicine, Humans, Prospective Studies, 030212 general & internal medicine, Young adult, Epidemics, education, Prospective cohort study, education.field_of_study, AIDS-Related Opportunistic Infections, business.industry, Mortality rate, Middle Aged, medicine.disease, Europe, Latin America, Female, business, Developed country, Demography, Cohort study
Abstract: Management of tuberculosis in patients with HIV in eastern Europe is complicated by the high prevalence of multidrug-resistant tuberculosis, low rates of drug susceptibility testing, and poor access to antiretroviral therapy (ART). We report 1 year mortality estimates from a multiregional (eastern Europe, western Europe, and Latin America) prospective cohort study: the TB:HIV study.Consecutive HIV-positive patients aged 16 years or older with a diagnosis of tuberculosis between Jan 1, 2011, and Dec 31, 2013, were enrolled from 62 HIV and tuberculosis clinics in 19 countries in eastern Europe, western Europe, and Latin America. The primary endpoint was death within 12 months after starting tuberculosis treatment; all deaths were classified according to whether or not they were tuberculosis related. Follow-up was either until death, the final visit, or 12 months after baseline, whichever occurred first. Risk factors for all-cause and tuberculosis-related deaths were assessed using Kaplan-Meier estimates and Cox models.Of 1406 patients (834 in eastern Europe, 317 in western Europe, and 255 in Latin America), 264 (19%) died within 12 months. 188 (71%) of these deaths were tuberculosis related. The probability of all-cause death was 29% (95% CI 26-32) in eastern Europe, 4% (3-7) in western Europe, and 11% (8-16) in Latin America (p0·0001) and the corresponding probabilities of tuberculosis-related death were 23% (20-26), 1% (0-3), and 4% (2-8), respectively (p0·0001). Patients receiving care outside eastern Europe had a 77% decreased risk of death: adjusted hazard ratio (aHR) 0·23 (95% CI 0·16-0·31). In eastern Europe, compared with patients who started a regimen with at least three active antituberculosis drugs, those who started fewer than three active antituberculosis drugs were at a higher risk of tuberculosis-related death (aHR 3·17; 95% CI 1·83-5·49) as were those who did not have baseline drug-susceptibility tests (2·24; 1·31-3·83). Other prognostic factors for increased tuberculosis-related mortality were disseminated tuberculosis and a low CD4 cell count. 18% of patients were receiving ART at tuberculosis diagnosis in eastern Europe compared with 44% in western Europe and 39% in Latin America (p0·0001); 12 months later the proportions were 67% in eastern Europe, 92% in western Europe, and 85% in Latin America (p0·0001).Patients with HIV and tuberculosis in eastern Europe have a risk of death nearly four-times higher than that in patients from western Europe and Latin America. This increased mortality rate is associated with modifiable risk factors such as lack of drug susceptibility testing and suboptimal initial antituberculosis treatment in settings with a high prevalence of drug resistance. Urgent action is needed to improve tuberculosis care for patients living with HIV in eastern Europe.EU Seventh Framework Programme.
Published: 2016

16. Diagnostik der Lyme-Borreliose

Author: Steffen I and Hirsch Hh
Subjects: Gynecology, medicine.medical_specialty, business.industry, Lyme borreliosis, medicine, Diagnostic test, General Medicine, business
Abstract: Die Verschiedenartigkeit der in Europa vorkommenden Borrelien, zusammengefasst als Borrelia burgdorferi sensu lato, erlaubt nicht, die für Borrelia burgdorferi sensu stricto in USA etablierten Definitionen und Tests ohne weiteres zu übernehmen. Durch die Erweiterung um Antigene der in Europa zusätzlich vorkommenden Subspezies B. afzelii und B. garinii bleibt der Nachweis der Borrelien-spezifischen Antikörper weiterhin der wichtigste Test in der Borrelien-Diagnostik: Screening mittels ELISA, Bestätigung durch Immunoblot. Der Erregernachweis mittels PCR oder, in spezialisierten Labors auch mittels Kultur, spielt trotz der hohen Spezifität wegen der tiefen Sensitivität nur eine untergeordnete Rolle. Unverändert gilt, dass Expositionsrisiko, Stadium und klinischer Verlauf die Wahl und Interpretation der diagnostischen Tests bestimmen.
Published: 2005
Full Text: View/download PDF

17. Virale Infektionen nach Transplantation

Author: Hirsch Hh
Subjects: Gynecology, medicine.medical_specialty, business.industry, medicine, General Medicine, business
Abstract: Morbidität und Mortalität einer Virusinfektion wird maßgeblich bestimmt durch Determinanten des Patienten (z. B. die Qualität und Quantität der Immuneffektoren, Grunderkrankung, Alter), des Grafts (z. B. Organ, HLA-mismatching, Schädigung, Permissivität für Virusinfektion) und des Virus (z. B. Genus, Tropismus, Fitness, Virostatikaresistenz). Diese «ménage-à-trois» von Patient, Graft und Virus wird durch zum Teil dosisabhängige Faktoren moduliert wie Immunsuppression, lokales und systemisches Entzündungs- und Zytokinmuster, Gabe von Immunglobulinen und/oder Virostatika. Diese Konzepte sind bei Infektionen mit Zytomegalievirus (CMV) am besten untersucht. Drei Gründe sind dafür verantwortlich: 1. Klinisch-virologische Definitionen von Infektion und Erkrankung; 2. quantitative Testverfahren mit schneller Ergebniserstellung; 3. Verfügbarkeit wirksamer Virostatika. Aus der spezifischen Transplantationskonstellation ergibt sich der prophylaktische, präemptive oder therapeutische Einsatz von Virostatika und Immunglobulinen. Weitere Fortschritte könnten sich durch die bessere Charakterisierung der zellulären Immunität ergeben. Mit der breiten Verfügbarkeit von quantitativen molekularen Messverfahren sind nun ebenfalls Fortschritte bei anderen, transplantationsrelevanten Virusinfektionen zu erwarten wie zum Beispiel Epstein-Barr-Virus, Polyomavirus BK oder respiratorische Viren.
Published: 2003
Full Text: View/download PDF

18. Development of a definition for rapid progression (RP) of renal function in HIV-positive persons:the D:A:D study

Author: Kamara, David A., Ryom, Lene, Ross, Michael, Kirk, Ole, Reiss, Peter, Morlat, Philippe, Moranne, Olivier, Fux, Christoph A., Mocroft, Amanda, Sabin, Caroline, Lundgren, Jens D., Smith, Colette J, D:A:D study, Group., Quiros, Roldan, Powderly B, M. E., Shortman, N, Moecklinghoff, C, Reilly, G, Franquet, X, Ryom, L, Sabin, Ca, Kamara, D, Smith, C, Phillips, A, Mocroft, A, Tverland, J, Mansfeld, M, Nielsen, J, Raben, D, Lundgren, Jd, Brandt, R, Rickenbach, M, Fanti, I, Krum, E, Hillebregt, M, Geffard, S, Sundström, A, Delforge, M, Fontas, E, Torres, F, Mcmanus, H, Wright, S, Kjær, J, Sjøl, A, Meidahl, P, Helweg-Larsen, J, Iversen, J, Kirk, O, Reiss, P, Ross, M, Fux, Ca, Morlat, P, Moranne, O, Kesselring, Am, Kamara, Da, Weber, R, Pradier, C, Friis-Møller, N, Kowalska, J, Sabin, C, Law, M, d'Arminio Monforte, A, Dabis, F, Bruyand, M, Bower, M, Fätkenheuer, G, Donald, A, Grulich, A, Zaheri, S, Gras, L, Prins, Jm, Kuijpers, Tw, Scherpbier, Hj, van der Meer JT, Wit, Fw, Godfried, Mh, van der Poll, D, Nellen, Fj, Lange, Jm, Geerlings, Se, van Vugt, M, Pajkrt, D, Bos, D, van der Valk, D, Grijsen, Ml, Wiersinga, Wj, Goorhuis, A, Hovius, Jw, Lowe, S, Lashof, A, Posthouwer, D, Ammerlaan, Hs, Pronk, Mj, van der Ende ME, de Vries-Sluijs TE, Schurink, Ca, Nouwen, Jl, Verbon, A, Rijnders, Bj, van Gorp EC, van der Feltz, M, Driessen, Gj, van Rossum AM, Branger, J, Schippers, F, van Nieuwkoop, C, van Elzakker EP, Groeneveld, Ph, Bouwhuis, Jw, Soetekouw, R, ten Kate RW, Kroon, Fp, van Dissel JT, Arend, Sm, de Boer MG, Jolink, H, ter Vollaard HJ, Bauer, Mp, den Hollander JG, Pogany, K, van Twillert, D, Kortmann, W, Stuart, Jw, Diederen, Bm, Leyten, Ms, Gelinck, Lb, Kootstra, Gj, Delsing, Ce, Brinkman, K, Blok, Wl, Frissen, Ph, Schouten, We, van den Berk GE, van Kasteren ME, Brouwer, Ae, Veenstra, J, Lettinga, Kd, Mulder, Jw, Vrouenraets, Sm, Lauw, Fn, van Eeden, A, Verhagen, Dw, Sprenger, Hg, Doedens, R, Scholvinck, Eh, van Assen, S, Bierman, Wf, Koopmans, Pp, Keuter, M, van der Ven AJ, ter Hofstede HJ, Dofferhoff, As, Warris, A, van Crevel, R, Hoepelman, Ai, Mudrikova, T, Schneider, Mm, Ellerbroek, Pm, Oosterheert, Jj, Arends, Je, Wassenberg, Mw, Barth, Re, van Agtmael, M, Perenboom, Rm, Claessen, Fa, Bomers, M, Peters, Ej, Geelen, Sp, Wolfs, Tf, Bont, Lj, Richter, C, van der Berg JP, Gisolf, Eh, van den Berge, M, Stegeman, A, van Vonderen MG, van Houte DP, Weijer, S, el Moussaoui, R, Winkel, C, Muskiet, F, Durand, Voigt, R, Chêne, G, Lawson-Ayayi, S, Thiébaut, R, Bonnal, F, Bonnet, F, Bernard, N, Caunègre, L, Cazanave, C, Ceccaldi, J, Chambon, D, Chossat, I, Dauchy, Fa, De Witte, S, Dupon, M, Duffau, P, Dutronc, H, Farbos, S, Gaborieau, V, Gemain, Mc, Gerard, Y, Greib, C, Hessamfar, M, Lacoste, D, Lataste, P, Lafarie, S, Lazaro, E, Malvy, D, Meraud, Jp, Mercié, P, Monlun, E, Neau, D, Ochoa, A, Pellegrin, Jl, Pistone, T, Ragnaud, Jm, Receveur, Mc, Tchamgoué, S, Vandenhende, Ma, Viallard, Jf, Moreau, Jf, Pellegrin, I, Fleury, H, Lafon, Me, Masquelier, B, Trimoulet, P, Breilh, D, Haramburu, F, Miremont-Salamé, G, Blaizeau, Mj, Decoin, M, Delaune, J, Delveaux, S, D'Ivernois, C, Hanapier, C, Leleux, O, Uwamaliya-Nziyumvira, B, Sicard, X, Palmer, G, Touchard, D, Petoumenos, K, Bendall, C, Moore, R, Edwards, S, Hoy, J, Watson, K, Roth, N, Nicholson, J, Bloch, M, Franic, T, Baker, D, Vale, R, Carr, A, Cooper, D, Chuah, J, Ngieng, M, Nolan, D, Skett, J, Calvo, G, Mateu, S, Domingo, P, Sambeat, Ma, Gatell, J, Del Cacho, E, Cadafalch, J, Fuster, M, Codina, C, Sirera, G, Vaqué, A, De Wit, S, Clumeck, N, Necsoi, C, Gennotte, Af, Gerard, M, Kabeya, K, Konopnicki, D, Libois, A, Martin, C, Payen, Mc, Semaille, P, Van Laethem, Y, Neaton, J, Bartsch, G, El-Sadr, Wm, Thompson, G, Wentworth, D, Luskin-Hawk, R, Telzak, E, Abrams, Di, Cohn, D, Markowitz, N, Arduino, R, Mushatt, D, Friedland, G, Perez, G, Tedaldi, E, Fisher, E, Gordin, F, Crane, Lr, Sampson, J, Baxter, J, Lundgren, J, Cozzi-Lepri, A, Grint, D, Podlekareva, D, Peters, L, Reekie, J, Fischer, Ah, Losso, M, Elias, C, Vetter, N, Zangerle, R, Karpov, I, Vassilenko, A, Mitsura, Vm, Suetnov, O, Colebunders, R, Vandekerckhove, L, Hadziosmanovic, V, Kostov, K, Machala, L, Begovac, J, Jilich, D, Sedlacek, D, Kronborg, G, Gerstoft, J, Benfield, T, Larsen, M, Katzenstein, T, Hansen, Ab, Skinhøj, P, Pedersen, C, Ostergaard, L, Zilmer, K, Smidt, J, Ristola, M, Katlama, C, Viard, J, Girard, P, Livrozet, Jm, Vanhems, P, Rockstroh, J, Schmidt, R, van Lunzen, J, Degen, O, Stellbrink, Hj, Staszewski, S, Bickel, M, Kosmidis, J, Gargalianos, P, Xylomenos, G, Perdios, J, Panos, G, Filandras, A, Karabatsaki, E, Sambatakou, H, Banhegyi, D, Mulcahy, F, Yust, I, Turner, D, Burke, M, Pollack, S, Hassoun, G, Maayan, S, Vella, S, Esposito, R, Mazeu, I, Mussini, C, Arici, C, Pristera, R, Mazzotta, F, Gabbuti, A, Vullo, V, Lichtner, M, Chirianni, A, Montesarchio, E, Gargiulo, M, Antonucci, G, Testa, A, Narciso, P, Vlassi, C, Zaccarelli, M, Lazzarin, A, Castagna, A, Gianotti, N, Galli, M, Ridolfo, A, Rozentale, B, Zeltina, I, Chaplinskas, S, Hemmer, R, Staub, T, Ormaasen, V, Maeland, A, Bruun, J, Knysz, B, Gasiorowski, J, Horban, A, Bakowska, E, Grzeszczuk, A, Flisiak, R, Boron-Kaczmarska, A, Pynka, M, Parczewski, M, Beniowski, M, Mularska, E, Trocha, H, Jablonowska, E, Malolepsza, E, Wojcik, K, Antunes, F, Doroana, M, Caldeira, L, Mansinho, K, Maltez, F, Duiculescu, D, Rakhmanova, A, Babes, V, Zakharova, N, Jevtovic, D, Mokráš, M, Staneková, D, Tomazic, J, González-Lahoz, J, Soriano, V, Labarga, P, Medrano, J, Moreno, S, Rodriguez, Jm, Clotet, B, Jou, A, Paredes, R, Tural, C, Puig, J, Bravo, I, Gatell, Jm, Miró, Jm, Gutierrez, M, Karlsson, A, Mateo, G, Flamholc, L, Ledergerber, B, Francioli, P, Cavassini, M, Hirschel, B, Boffi, E, Kravchenko, E, Furrer, H, Battegay, M, Elzi, L, Chentsova, N, Frolov, V, Kutsyna, G, Servitskiy, S, Krasnov, M, Barton, S, Johnson, Am, Mercey, D, Johnson, Ma, Murphy, M, Weber, J, Scullard, G, Fisher, M, Leen, C, Morfeldt, L, Thulin, G, Åkerlund, B, Koppel, K, Håkangård, C, Moroni, M, Angarano, G, Antinori, A, Armignacco, O, Castelli, F, Cauda, R, Di Perri, G, Iardino, R, Ippolito, G, Perno, Cf, von Schloesser, F, Viale, P, Ceccherini-Silberstein, F, Girardi, E, Lo Caputo, S, Puoti, M, Andreoni, M, Ammassari, A, Balotta, C, Bonfanti, P, Bonora, S, Borderi, M, Capobianchi, Mr, Cingolani, A, Cinque, P, De Luca, A, Di Biagio, A, Gori, A, Guaraldi, G, Lapadula, G, Madeddu, G, Maggiolo, F, Marchetti, G, Marcotullio, S, Monno, L, Quiros, E, Rusconi, S, Cicconi, P, Formenti, T, Galli, L, Lorenzini, P, Giacometti, A, Costantini, A, Santoro, C, Suardi, C, Vanino, E, Verucchi, G, Quiros Roldan, E, Minardi, C, Quirino, T, Abeli, C, Manconi, Pe, Piano, P, Vecchiet, J, Falasca, K, Sighinolfi, L, Segala, D, Cassola, G, Viscoli, G, Alessandrini, A, Piscopo, R, Mazzarello, G, Mastroianni, C, Belvisi, V, Caramma, I, Castelli, Ap, Rizzardini, G, Ridolfo, Al, Piolini, R, Salpietro, S, Carenzi, L, Moioli, Mc, Puzzolante, C, Onofrio, M, Abrescia, N, Guida, Mg, Baldelli, F, Francisci, D, Parruti, G, Ursini, T, Magnani, G, Ursitti, Ma, d' Avino, A, Gallo, L, Nicastri, E, Acinapura, R, Capozzi, M, Libertone, R, Tebano, G, Cattelan, A, Mura, Ms, Caramello, P, Orofino, Gc, Sciandra, M, Pellizzer, G, Manfrin, V, Caissotti, C, Dellamonica, P, Bernard, E, Cua, E, De Salvador- Guillouet, F, Durant, J, Ferrando, S, Mondain-Miton, V, Naqvi, A, Perbost, I, Prouvost-Keller, B, Pillet, S, Pugliese, P, Rahelinirina, V, Roger, Pm, Dollet, K, Aubert, V, Barth, J, Bernasconi, E, Böni, J, Bucher, Hc, Burton- Jeangros, C, Calmy, A, Egger, M, Fehr, J, Fellay, J, Gorgievski, M, Günthard, H, Haerry, D, Hasse, B, Hirsch, Hh, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kovari, H, Martinetti, G, de Tejada BM, Metzner, K, Müller, N, Nadal, D, Pantaleo, G, Rauch, A, Regenass, A, Rudin, C, Schmid, P, Schultze, D, Schöni-Affolter, F, Schüpbach, J, Speck, R, Taffé, P, Tarr, P, Telenti, A, Trkola, A, Vernazza, P, Yerly, S., AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Global Health, Other departments, Infectious diseases, Paediatric Infectious Diseases / Rheumatology / Immunology, General Internal Medicine, Dermatology, Medical Microbiology and Infection Prevention, Sea to Shore Alliance, University of Florida [Gainesville] (UF), Observatoire des Micro et Nano Technologies (OMNT - UMS 2920), Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information (CEA-LETI), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Structures et propriétés d'architectures moléculaire (SPRAM - UMR 5819), Institut Nanosciences et Cryogénie (INAC), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Service de médecine interne et maladies infectieuses [Bordeaux], CHU Bordeaux [Bordeaux]-Groupe hospitalier Saint-André, Département de santé publique, Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital Larchet, Service de néphrologie, Hôpital Pasteur [Nice] (CHU)-Centre Hospitalier Universitaire de Nice (CHU Nice), Department of primary care and population sciences, University College of London [London] (UCL), Research Department of Infection and Population Health [London], Economics, Umeå University, Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Institut Nanosciences et Cryogénie (INAC), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])
Subjects: Adult, Male, CHRONIC KIDNEY-DISEASE, Internationality, FUNCTION DECLINE, diagnosis, nephrology, Chronic kidney disease, Estimated glomerular filtration rate, HIV, Kidney disease, Rapid progression, D:A:D study Group, HIV Infections, urologic and male genital diseases, Sensitivity and Specificity, Severity of Illness Index, GLOMERULAR-FILTRATION-RATE, renal insufficiency, NO, MORTALITY RISK, ANTIRETROVIRAL THERAPY, 80 and over, Humans, chronic kidney disease, estimated glomerular filtration rate, hiv, kidney disease, rapid progression, adult, aged, aged, 80 and over, diagnosis, computer-assisted, disease progression, female, glomerular filtration rate, hiv infections, humans, internationality, male, middle aged, renal insufficiency, chronic, reproducibility of results, sensitivity and specificity, algorithms, severity of illness index, Diagnosis, Computer-Assisted, Renal Insufficiency, Chronic, ComputingMilieux_MISCELLANEOUS, BODY-SURFACE AREA, POPULATION, Aged, Aged, 80 and over, INFECTED PATIENTS, Reproducibility of Results, 1103 Clinical Sciences, ASSOCIATION, Urology & Nephrology, Middle Aged, chronic, INDIVIDUALS, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, computer-assisted, Disease Progression, Female, Algorithms, Research Article, Glomerular Filtration Rate
Abstract: BACKGROUND: No consensus exists on how to define abnormally rapid deterioration in renal function (Rapid Progression, RP). We developed an operational definition of RP in HIV-positive persons with baseline estimated glomerular filtration rate (eGFR) >90 ml/min/1.73 m2 (using Cockcroft Gault) in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study from 2004 to 2011. METHODS: Two definitions were evaluated; RP definition A: An average eGFR decline (slope) ≥5 ml/min/1.73 m2/year over four years of follow-up with ≥3 eGFR measurements/year, last eGFR
Published: 2014

19. Adhärenz, pharmakokinetischer «Toleranzbereich» und HIV-Resistenzbildung

Author: Erik Mossdorf and Hirsch Hh
Subjects: Gynecology, medicine.medical_specialty, business.industry, Medicine, General Medicine, business
Abstract: Anlässlich einer Kontrolle wird bei einem 43-jährigen, HIV-positiven Patienten mit ART neu eine HIV-Viruslast von 2032 Kopien/mL festgestellt. Zuvor war unter einer Therapie mit Lamivudin und Zidovudin (NRTI) sowie Nelfinavir (nicht-geboosteter PI) die Viruslast während 18 Monaten undetektierbar (< 50 Kopien/mL). Es konnte die Diagnose einer sekundären HIV-Resistenz des ungeboosteten PIs bei pharmakokinetischer Non-Adhärenz gestellt werden. Die HIV-Resistenzprüfung legte eine Salvage-Therapie mit einem geboosteten PI nahe. Neben der regelmässigen Medikamenteneinnahme erbringen diese antiretroviralen Medikamente mit ihren hohen Serumspiegeln und langen Halbwertszeiten eine dauerhafte Virussuppression und vermindern das Risiko von Resistenzentwicklungen.
Published: 2006
Full Text: View/download PDF

20. In-vitro-Evaluierung der MR-Thermometrie zum Einsatz der laserinduzierten Thermotherapie

Author: P K Müller, Th. Vogl, R. Felix, Peter Wust, Weinhold N, Andre Roggan, M. G. Mack, Philipp C, and Hirsch Hh
Subjects: Temperature sensitivity, Materials science, Nuclear magnetic resonance, Laser-induced thermotherapy, law, Mr thermometry, Radiology, Nuclear Medicine and imaging, Laser, Pig liver, Temperature measurement, law.invention
Abstract: PURPOSE To optimize the MR sequences parameter for monitoring hyperthermic effects in the tissue during laser induced thermotherapy (LITT). MATERIAL AND METHODS Experimental studies were performed for the evaluation of MR-thermometry using a contrast-agent-water solution and a pig-liver. A T1-weighted TurboFLASH sequence and a FLASH-2D sequence were used. The TurboFLASH sequence was used with various T1 settings (between 100 and 1250 ms). MR findings were correlated with temperature measurements using a fluoride optical temperature measuring system in a distance of 1, 2, and 5 cm from the laser applicator. RESULTS Using the contrast-agent-water solution demonstrated the temperature sensitivity of both sequences. In vitro evaluations using pig liver demonstrated a near linear increase of signal versus increasing tissue temperatures in a distance of 1 cm to the tip of the laser applicator. Optimal visualization of the temperature effects was obtained using a T1 between 100 ms and 400 ms. Using the FLASH-2D sequence a signal loss was documented at a TR of 110 ms. CONCLUSION MR-thermometry using sequentially TurboFLASH and FLASH-2D sequences allowed a non-invasive monitoring of the laser induced temperature changes.
Published: 1997
Full Text: View/download PDF

21. Missed opportunities among HIV-positive women to control viral replication during pregnancy and to have a vaginal delivery

Author: Aebi Popp, K, Mulcahy, F, Glass, Tr, Rudin, C, Martinez de Tejada, B, Bertisch, B, Fehr, J, Grawe, C, Scheibner, K, Rickenbach, M, Hoesli, I, Thorne, C, European Collaborative Study in EuroCoord, Swiss, Mother, Child HIV Cohort Study Collaborators: Thorne, C, Bailey, H, Giaquinto, C, Rampon, O, Mazza, A, De Rossi, A, Wörner, I, Mok, J, de José MI, Martínez, B, Peña, J, Garcia, J, Lopez, Jr, Rodriguez, Mc, Asensi Botet, F, Otero, Mc, Pérez Tamarit, D, Scherpbier, Hj, Kreyenbroek, M, Godfried, Mh, Nellen, Fj, Boer, K, Navér, L, Bohlin, Ab, Lindgren, S, Kaldma, A, Belfrage, E, Levy, J, Barlow, P, Manigart, Y, Hainaut, M, Goetghebuer, T, Brichard, B, De Camps, J, Thiry, N, Deboone, G, Waterloos, H, Viscoli, C, De Maria, A, Bentivoglio, G, Ferrero, S, Gotta, C, Mûr, A, Payà, A, López Vilchez MA, Carreras, R, Valerius, Nh, Rosenfeldt, V, Coll, O, Suy, A, Perez, J, Fortuny, C, Boguña, J, Savasi, V, Fiore, S, Crivelli, M, Viganò, A, Giacomet, V, Cerini, C, Raimondi, C, Zuccotti, G, Alberico, S, Maso, G, Tropea, M, Barresi, V, Taylor, G, Lyall, Eg, Penn, Z, Buffolano, W, Tiseo, R, Martinelli, P, Sansone, M, Maruotti, G, Agangi, A, Tibaldi, C, Marini, S, Masuelli, G, Benedetto, Chiara, Niemieç, T, Marczynska, M, Dobosz, S, Popielska, J, Oldakowska, A, Aubert, V, Barth, J, Battegay, M, Bernasconi, E, Böni, J, Brazzola, P, Bucher, Hc, Burton Jeangros, C, Calmy, A, Cavassini, M, Cheseaux, Jj, Drack, G, Duppenthaler, A, Egger, M, Elzi, L, Fellay, J, Francini, K, Furrer, H, Fux, Ca, Gorgievski, M, Günthard, H, Haerry, D, Hasse, B, Hirsch, Hh, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kovari, H, Ledergerber, B, Martinetti, G, de Tejada, B, Metzner, K, Müller, N, Nadal, D, Pantaleo, G, Polli, Ch, Posfay Barbe, K, Rauch, A, Regenass, S, Schmid, P, Schultze, D, Schöni Affolter, F, Schüpbach, J, Speck, R, Taffé, P, Tarr, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, Wyler, Ca, Yerly, S., Posfay Barbe, Klara, Wyler, Claire-Anne, University of Zurich, Aebi-Popp, Karoline, Aebi Popp, K, Mulcahy, F, Glass, Tr, Rudin, C, Martinez de Tejada, B, Bertisch, B, Fehr, J, Grawe, C, Scheibner, K, Rickenbach, M, Hoesli, I, Buffolano, Wilma, Thorne, C, European Collaborative Study in, Eurocoord, Swiss, Mother, and Child HIV Cohort, S. t. u. d. y.
Subjects: mode of delivery, medicine.medical_treatment, HIV Infections, Delivery, Obstetric/statistics & numerical data, Virus Replication, 10234 Clinic for Infectious Diseases, Cohort Studies, HIV Infections/drug therapy/prevention & control/transmission, Pregnancy, Antiretroviral Therapy, Highly Active, 2736 Pharmacology (medical), Pharmacology (medical), Surgical Procedures, Elective/statistics & numerical data, Pregnancy Complications, Infectious, Europe, HIV, Mode of delivery, Adult, Anti-HIV Agents, Cesarean Section, Delivery, Obstetric, Drug Therapy, Combination, Elective Surgical Procedures, Female, Guidelines as Topic, Health Policy, Humans, Infant, Newborn, Infectious Disease Transmission, Vertical, Viral Load, Infectious Diseases, ddc:618, Obstetrics, Vaginal delivery, Transmission (medicine), Cesarean Section/statistics & numerical data, Meta-analysis, provvedimento amministrativo - nullità - domanda riconvenzionale, Viral load, Cohort study, medicine.medical_specialty, Pregnancy Complications, Infectious/drug therapy/epidemiology/prevention & control, 610 Medicine & health, Europe/epidemiology, Pharmacotherapy, medicine, Caesarean section, business.industry, 2725 Infectious Diseases, medicine.disease, Viral Load/drug effects, HIV, pregnancy, mode of delivery, Anti-HIV Agents/therapeutic use, Settore MED/40 - Ginecologia e Ostetricia, business, Infectious Disease Transmission, Vertical/prevention & control/statistics & numerical data
Abstract: INTRODUCTION: Most national guidelines for the prevention of mother-to-child transmission of HIV in Europe updated between 2001 and 2010 recommend vaginal deliveries for women with undetectable or very low viral load (VL). Our aim was to explore the impact of these new guidelines on the rates of vaginal deliveries among HIV-positive women in Europe. METHODS: In a pooled analysis of data on HIV-positive pregnant women enrolled in the Swiss Mother & Child HIV Cohort Study and the European Collaborative Study 2000 to 2010, deliveries were classified as occurring pre- or postpublication of national guidelines recommending vaginal delivery. RESULTS: Overall, 2663 women with 3013 deliveries were included from 10 countries; 28% women were diagnosed with HIV during pregnancy. Combination antiretroviral therapy was used in most pregnancies (2020, 73%), starting during the first or second trimester in 78% and during the third trimester in 22%; in 25% pregnancies, the woman conceived on combination antiretroviral therapy. Overall, in 86% pregnancies, a VL < 400 copies per milliliter was achieved before delivery. The proportion of vaginal deliveries increased from 17% (414/2377) before the change in guidelines to 52% (313/600) after; elective Caesarean section rates decreased from 65% to 27%. The proportion of women with undetectable VL having a Caesarean section was 55% after implementation of new guidelines. We observed a decrease of late preterm deliveries from 16% (377/2354) before to 7% (42/599) after the change in guidelines (P < 0.001). CONCLUSION: There are still missed opportunities for women with HIV to fully suppress their VL and to deliver vaginally in Europe.
Published: 2013

22. Expansion of interferon-γ-secreting HIV-specific T cells during successful antiretroviral therapy

Author: Gasser, O, Brander, C, Wolbers, M, Brown, NV, Rauch, A, Günthard, HF, Battegay, M, Hess, C, Bernasconi, E, Böni, J, Bucher, HC, Bürgisser, P, Calmy, A, Cattacin, S, Cavassini, M, Dubs, R, Egger, M, Elzi, L, Fischer, M, Flepp, M, Fontana, A, Francioli, P, Furrer, H, Fux, CA, Gorgievski, M, Günthard, H, Hirsch, HH, Hirschel, B, Hösli, I, Kahlert, C, Kaiser, L, Karrer, U, Kind, C, Klimkait, T, Ledergerber, B, Martinetti, G, Müller, N, Nadal, D, Paccaud, F, Pantaleo, G, Regenass, S, Rickenbach, M, Rudin, C, Schmid, P, Schultze, D, Schüpbach, J, Speck, R, de Tejada, BM, Taffé, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, and Yerly, S
Abstract: Objectives: Antiretroviral therapy (ART) suppresses HIV viraemia, thereby reducing the antigenic drive for T cells to proliferate. Accordingly, selected HIV-specific T-cell responses have been described to contract within weeks of ART initiation. Here, we sought to investigate whether these findings apply to the entire repertoire of HIV-specific T cells. Methods: Using interferon (IFN)-γ enzyme linked immuno spot (ELISpot), we performed retrospective 2-year proteome-wide monitoring of HIV-specific T cells in 17 individuals with undetectable viral loads during ART. The sample pool for each study subject consisted of one pre-ART time-point and at least two time-points after initiation of therapy. Results: Peripheral pools of HIV-specific T cells decreased nonsignificantly within the first 2 years under ART in our cohort of patients, in terms of both breadth and magnitude. However, in most cases, the seeming decrease masked ongoing expansion of individual HIV-specific T-cell responses. We detected synchronous contraction and expansion of T-cell responses - with different peptide specificities - in 12 out of 17 study participants during follow-up. Importantly, the observed expansions and contractions of individual HIV-specific T-cell responses reached similar ranges, supporting the biological relevance of our findings. Conclusions: We conclude that successful ART enables both contraction and expansion of HIV-specific T-cell responses. Our results should prompt a renewed interest in HIV-specific T-cell dynamics under ART, in particular to elucidate the mechanisms that uncouple, to some extent, particular HIV-specific T-cell responses from variations in circulating antigen load and functionally characterize expanding/contracting T-cell populations beyond IFN-γ secretion. Assuming that expanding HIV-specific T-cell responses under ART are protective and functional, harnessing those mechanisms may provide novel opportunities for assisting viral control in chronically infected individuals. © 2012 British HIV Association.
Published: 2013

23. Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for Diagnosis and Treatment of Human Respiratory Syncytial Virus, Parainfluenza Virus, Metapneumovirus, Rhinovirus, and Coronavirus

Author: Hirsch, HH, Martino, R, Ward, KN, Boeckh, M, Einsele, H, and Ljungman, P
Subjects: bone marrow transplantation, leukemia, hematopoietic, respiratory virus, transplantation
Abstract: Community-acquired respiratory virus (CARV) infections have been recognized as a significant cause of morbidity and mortality in patients with leukemia and those undergoing hematopoietic stem cell transplantation (HSCT). Progression to lower respiratory tract infection with clinical and radiological signs of pneumonia and respiratory failure appears to depend on the intrinsic virulence of the specific CARV as well as factors specific to the patient, the underlying disease, and its treatment. To better define the current state of knowledge of CARVs in leukemia and HSCT patients, and to improve CARV diagnosis and management, a working group of the Fourth European Conference on Infections in Leukaemia (ECIL-4) 2011 reviewed the literature on CARVs, graded the available quality of evidence, and made recommendations according to the Infectious Diseases Society of America grading system. Owing to differences in screening, clinical presentation, and therapy for influenza and adenovirus, ECIL-4 recommendations are summarized for CARVs other than influenza and adenovirus.
Published: 2013

24. Koagulase-negative Staphylokokken auf der Haut – immer harmlos?

Author: Ramseier E, Fehr J, and Hirsch Hh
Subjects: biology, business.industry, Medicine, General Medicine, Staphylococcus lugdunensis, biology.organism_classification, business, Microbiology
Abstract: Beschrieben werden rezidivierende Hautinfektionen (Furunkulose, Follikulitis) mit koagulase-negativen Staphylokokken. Die Speziesbestimmung ergab Staph. lugdunensis, der Staph. aureus-ähnlich Virulenz zeigen kann. Eine Dekontaminationsstrategie war nachhaltig erfolgreich. Gegebenfalls ist eine Behandlung von kolonisierten/symptomatischen Familienmitgliedern indiziert.
Published: 2004
Full Text: View/download PDF

25. Clinical relevance of cytomegalovirus viraemia(*,†)

Author: El Amari, E Boffi, Combescure, Christophe, Yerly Ferrillo, Sabine, Calmy, Alexandra, Kaiser, Laurent, Hasse, B, Furrer, H, Cavassini, M, Vernazza, P, Hirsch, Hh, Bernasconi, Enos, Hirschel, Bernard, University of Zurich, and El Amari, E B
Subjects: ddc:616, Adult, Male, Polymerase Chain Reaction/methods, virus diseases, Multiple Organ Failure/genetics/mortality/virology, HIV Infections/complications, 610 Medicine & health, Viremia/diagnosis/genetics/virology, 2725 Infectious Diseases, Cytomegalovirus/isolation & purification, Middle Aged, Viral Load, Sensitivity and Specificity, 2719 Health Policy, 10234 Clinic for Infectious Diseases, Switzerland/epidemiology, Cytomegalovirus Infections/genetics/mortality/virology, AIDS-Related Opportunistic Infections/genetics/mortality/virology, DNA, Viral/analysis, Humans, 2736 Pharmacology (medical), Female, Prospective Studies
Abstract: Using new sensitive quantitative polymerase chain reaction (PCR) assays, cytomegalovirus (CMV) DNA is often detectable in the plasma of immunosuppressed patients. We investigated the prognostic value of a positive CMV DNA test for the development of CMV end-organ disease, other AIDS-defining events and mortality.
Published: 2011

26. Molecular diagnostics for bacterial infections in bronchoalveolar lavage – a case-control, pilot study

Author: Jahn, K, primary, Kuisma, M, additional, Mäki, M, additional, Grendelmeier, P, additional, Hirsch, HH, additional, Tamm, M, additional, Papakonstantinou, E, additional, and Stolz, D, additional
Published: 2015
Full Text: View/download PDF

27. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study

Author: Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients, Lodwick, Rk, Sabin, Ca, Porter, K, Ledergerber, B, van Sighem, A, Cozzi Lepri, A, Khaykin, P, Mocroft, A, Jacobson, L, De Wit, S, Obel, N, Castagna, A, Wasmuth, Jc, Gill, J, Klein, Mb, Gange, S, Riera, M, Mussini, C, Gutiérrez, F, Touloumi, G, Carrieri, P, Guest, Jl, Brockmeyer, Nh, Collaborators: Antoniadou A, Phillips A. N., Gargalianos Kakolyris, P, Katsarou, O, Kordossis, T, Lazanas, M, Panos, G, Paparizos, V, Paraskevis, D, Petrikkos, G, Sambatakou, H, Skoutelis, A, Pantazis, N, Bakoyannis, G, Gioukari, V, de Wolf, F, Bezemer, Do, Gras, La, Kesselring, Am, van Sighem AI, Smit, C, Zhang, S, Zaheri, S, Prins, Jm, Schreij, G, Bravenboer, B, van der Ende ME, Kauffmann, Rh, ten Kate RW, Kroon, Fp, Bronsveld, W, Vriesendorp, R, van Houte, D, ten Napel CH, Brinkman, K, van Eeden, A, Mulder, Jw, Juttmann, Jr, Veenstra, J, Koopmans, Pp, Sprenger, Hg, Hoepelman, Im, Danner, Sa, Richter, C, Tanis, Aa, Clumeck, N, Delforge, M, Necsoi, C, Demeester, R, Gennotte, Af, Gerard, M, Guillaume, Mp, Hermans, P, Kabeya, K, Konopnicki, D, Martin, C, Libois, A, Payen, Mc, Semaille, P, Van Laethem, Y, Del Amo, J, Meyer, L, Bucher, Hc, Chêne, G, Pillay, D, Prins, M, Rosinska, M, Sabin, C, Lodi, S, Coughlin, K, Walker, S, Babiker, A, Bucher, H, de Luca, A, Fisher, M, Muga, R, Fätkenheuer, G, Rockstroh, J, Vehreschild, J, Hertenstein, C, Berenguer, J, del Amo, J, García, F, Labarga, P, Moreno, S, Angeles Muñoz, M, Caro Murillo AM, Sobrino, P, Pérez Cachafeiro, S, Jarrín, I, Alejos, B, García, I, Gómez Sirvent, J, Soriano, V, Pulido, F, Iribarren, J, Masiá, M, Vidal, F, Sanz, J, Blanco, Ja, Sola, J, Gerstoft, J, Kronborg, G, Røge, B, Larsen, Cs, Pedersen, G, Laursen, Al, Nielsen, L, Jensen, J, Babacan, E, Bickel, M, Bodtländer, A, Brodt, Hr, Carlebach, A, Gute, P, Haberl, A, Helm, E, Klauke, S, Knecht, G, Lennemann, T, Locher, L, Lutz, T, Mösch, M, Müller, A, Nisius, G, Staszewski, S, Stephan, C, Stürmer, M, von Hentig, N, Wolf, T, Rimland, D, Moanna, A, Moorfield, M, Dorsey, M, Desilva, Ke, Schlueter Wirtz, S, Mindley, R, Dozier, R, Robinson, Y, Brown, P, Moroni, M, Angarano, G, Antinori, A, Carosi, G, Cauda, R, d'Arminio Monforte, A, Di Perri, G, Galli, M, Ghinelli, G, Iardino, R, Ippolito, G, Lazzarin, A, Mazzotta, F, Perno, Cf, Viale, Pl, Von Schlosser, F, Ammassari, A, Balotta, C, Bonfanti, P, Capobianchi, Mr, Ceccherini Silberstein, F, De Luca, A, Gervasoni, C, Girardi, E, Lo Caputo, S, Maggiolo, F, Murri, R, Puoti, M, Torti, Carlo, Salpietro, S, Marangione, M, Galli, L, Gianotti, N, Cossarini, F, Spagnuolo, V, Arendt, G, Esser, S, Jäger, H, Schwarze, S, Stoll, M, Wolf, H, Jansen, K, Michalik, C, Skaletz Rorowski, A, Königs, C, Gingelmaier, A, Margolick, Jb, Jacobson, Lp, Phair, Jp, Wolinsky, Sm, Detels, R, Rinaldo, Cr, Boirot, C, Bouhnik, Ad, Carrieri, Mp, Cassuto, Jp, Chesney, M, Cohen, J, Dellamonica, P, Dujardin, P, Gallais, H, Gastaut, Ja, Kurkdji, P, Lepeu, G, Mechali, D, Moatti, Jp, Moreau, J, Nègre, M, Obadia, Y, Poizot Martin, I, Pradier, C, Préau, M, Rey, D, Roux, P, Rouzioux, C, Sobel, A, Spire, B, Trémolières, F, Villes, V, Vincent, E, Vlahov, D, Borghi, V, Casabona, J, Miró, Jm, Gatell, Jm, López Dieguez Puerta, M, Tural, C, Clotet, B, Podzamczer, D, Ferrer, E, Murillas, J, Segura, F, Navarro, G, Force, L, Vilaró, J, Masabeu, A, Guadarrama, M, Betancourt, Aj, Romero, A, Agustí, C, Battegay, M, Bernasconi, E, Böni, J, Bürgisser, P, Calmy, A, Cavassini, M, Dubs, R, Egger, M, Elzi, L, Fischer, M, Flepp, M, Fontana, A, Francioli, P, Furrer, H, Fux, Ca, Gorgievski, M, Günthard, Hf, Hirsch, Hh, Hirschel, B, Hösli, I, Kahlert, C, Kaiser, L, Karrer, U, Kind, C, Klimkait, T, Martinetti, G, Martinez, B, Müller, N, Nadal, D, Paccaud, F, Pantaleo, G, Rauch, A, Regenass, S, Rickenbach, M, Rudin, C, Schmid, P, Schultze, D, Schöni, F, Schüpbach, J, Speck, R, Taffé, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, Yerly, S, Ainsworth, J, Anderson, J, Delpech, V, Dunn, D, Easterbrook, P, Gazzard, B, Gilson, R, Gompels, M, Hill, T, Johnson, M, Leen, C, Nelson, M, Orkin, C, Palfreeman, A, Phillips, A, Post, F, Schwenk, A, Walsh, J, Bansi, L, Huntington, S, Glabay, A, Anastos, K, Minkoff, H, Young, M, Greenblatt, R, Levine, A, Cohen, M, and Gange, S.
Published: 2010

28. Wie häufig kann die klinische Diagnose des Dreitagefiebers mit der HHV-6-Serologie bestätigt werden?

Author: Hirsch Hh and Rudin C
Subjects: medicine.medical_specialty, biology, business.industry, Roseola Infantum, medicine.disease_cause, biology.organism_classification, Dermatology, Herpesviridae, Serology, Private practice, Alphaherpesvirinae, Pediatrics, Perinatology and Child Health, Immunology, medicine, biology.protein, Viral disease, Seroconversion, Antibody, business
Abstract: Three years ago a newly recognized human herpes virus (HHV-6) was identified to be the causative agent for exanthem subitum (roseola infantum). So far this diagnosis was suggested chiefly by excluding other infections and the presence of a typical course of the disease. To find out how often the clinical diagnosis can be confirmed serologically, we asked five pediatricians in private practice as well as residents of the out-patient and infant departments of our hospital to obtain paired heparinized blood samples of any child suspicious for exanthem subitum. 36 children with clinically suspected exanthem subitum and a mean age of 14.2 (5-71) months were included in this prospective study. Indirect immunofluorescence was used to detect IgG and IgM antibodies to HHV-6. In 22 children (61%) the clinical diagnosis was confirmed serologically. IgM antibody was found in only 16 of these 22 children. In 8 patients the results were ambiguous. Three had in the same time a doubtful seroconversion to other viruses of the herpes group (HSV twice; EBV once), in four children there was an insufficient rise in IgG antibodies without presence of an IgM response, and once we found a very high HHV-6 specific antibody titre (greater than 1:80) in both serum samples. In 6 children neither a seroconversion nor a rise in HHV-6 antibody titre were found. Retrospectively, only three of these children had a clinical course really typical for exanthem subitum. We conclude that in most cases the clinical diagnosis of exanthem subitum will be confirmed by serological examination.(ABSTRACT TRUNCATED AT 250 WORDS)
Published: 1991
Full Text: View/download PDF

29. Current preventive strategies and management of Epstein–Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey

Author: San Juan, R, Manuel, O, Hirsch, Hh, Fernández Ruiz, M, López Medrano, F, Comoli, P, Caillard, S, Grossi, P, Aguado, Jm, Álamo Martínez JM, Anaya, F, Anttila, Vj, Arnol, M, Avolio, Aw, Baccarani, U, Castello, Ib, Boletis, I, Bonofiglio, R, Viamigliori, A, Bressollette, C, Brockmann, J, Pulido, Jc, Catalán, P, Christiansen, C, Cofan, F, Cordero, E, Leiro, Mc, Dantal, J, D'Armini, A, Delgado, Jf, Dello Strologo, L, Gesu, B, DI RAIMONDO, Francesco, Dierickx, D, Eis Hübinger, A, Kremer, Sf, Faggian, G, Fariñas, Mc, Folgueira, Md, Fontana, I, Franco, A, Furian, L, Garzoni, C, Ghirardo, G, Ginevri, F, Grinyó, J, Grossi, Pa, Gupte, G, Hansson, L, Helanterä, I, Herrero, Ji, Hobin, D, Hoffmann, D, Jan, L, Jarque, I, Jespersen, B, Kaczmarek, I, Klin, G, Kevin, P, Koneth, I, Kovac, D, Lacaille, F, Lautenschlager, I, Len, O, Lladó, L, Loy, M, Maeso, Ma, Marianne, Lv, Marsh, J, Meylan, P, Miñambres, E, Montejo, M, Mueller, N, Muñoz, P, Nadalin, S, Kamar, N, Nicolas, B, Olivier, D, Palomo, J, Pascual, M, Peter, J, Pierre, F, Portero, Mf, Provot, F, Boluda, Er, Regalia, E, Reina, G, Reuter, S, Ricart, Mj, García, Mr, Rollag, H, Russo, Fp, Sabé, N, Salcedo, M, Santambrogio, L, Seeman, T, Serra, N, Sgarabotto, D, Simonek, J, Thierry, Y, Thomsen, Mk, Tihic, N, Torre Cisneros, J, Travi, G, Tulissi, P, Moal, V, Veroux, Massimiliano, Santandreu, Av, Vizzini, G, Zibar, L., Clinicum, Department of Medicine, Infektiosairauksien yksikkö, Department of Virology, and Medicum
Subjects: Epstein-Barr Virus Infections, Cross-sectional study, Settore MED/18 - CHIRURGIA GENERALE, medicine.medical_treatment, Medizin, Epstein-Barr virus, Europe, Post-transplant lymphoproliferative disease, Pre-emptive treatment, Survey, Microbiology (medical), Infectious Diseases, medicine.disease_cause, Organ transplantation, Epstein–Barr virus, Surveys and Questionnaires, hemic and lymphatic diseases, Medicine, Tomography, TOR Serine-Threonine Kinases, Immunosuppression, General Medicine, Viral Load, pre-emptive treatment, X-Ray Computed, 3. Good health, Cross-Sectional Studies, Humans, Immunosuppressive Agents, Lymphoproliferative Disorders, Positron-Emission Tomography, Rituximab, Tomography, X-Ray Computed, Viremia, Organ Transplantation, Transplant Recipients, post-transplant lymphoproliferative disease, Viral load, medicine.drug, medicine.medical_specialty, survey, Internal medicine, business.industry, Immunology, 3111 Biomedicine, business, Solid organ transplantation, Serostatus
Abstract: There is limited clinical evidence on the utility of the monitoring of Epstein–Barr virus (EBV) DNAemia in the pre-emptive management of post-transplant lymphoproliferative disease (PTLD) in solid organ transplant (SOT) recipients. We investigated current preventive measures against EBV-related PTLD through a web-based questionnaire sent to 669 SOT programmes in 35 European countries. This study was performed on behalf of the ESGICH study group from the European Society of Clinical Microbiology and Infectious Diseases. A total of 71 SOT programmes from 15 European countries participated in the study. EBV serostatus of the recipient is routinely obtained in 69/71 centres (97%) and 64 (90%) have access to EBV DNAemia assays. EBV monitoring is routinely used in 85.9% of the programmes and 77.4% reported performing pre-emptive treatment for patients with significant EBV DNAemia levels. Pre-emptive treatment for EBV DNAemia included reduction of immunosuppression in 50.9%, switch to mammalian target of rapamycin inhibitors in 30.9%, and use of rituximab in 14.5% of programmes. Imaging by whole-body 18-fluoro-deoxyglucose positron emission tomography (FDG-PET) is used in 60.9% of centres to rule out PTLD and complemented computer tomography is used in 50%. In 10.9% of centres, FDG-PET is included in the first-line diagnostic workup in patients with high-risk EBV DNAemia. Despite the lack of definitive evidence, EBV load measurements are frequently used in Europe to guide diagnostic workup and pre-emptive reduction of immunosuppression. We need prospective and controlled studies to define the impact of EBV monitoring in reducing the risk of PTLD in SOT recipients.
Published: 2015
Full Text: View/download PDF

30. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study

Author: Hirsch, Hh, Vincenti, F, Friman, S, Tuncer, M, Citterio, Franco, Wiecek, A, Scheuermann, Eh, Klinger, M, Russ, G, Pescovitz, Md, Prestele, H., Citterio, Franco (ORCID:0000-0003-0489-6337), Hirsch, Hh, Vincenti, F, Friman, S, Tuncer, M, Citterio, Franco, Wiecek, A, Scheuermann, Eh, Klinger, M, Russ, G, Pescovitz, Md, Prestele, H., and Citterio, Franco (ORCID:0000-0003-0489-6337)
Abstract: Polyomavirus BK (BKV)-associated nephropathy causes premature kidney transplant (KT) failure. BKV viruria and viremia are biomarkers of disease progression, but associated risk factors are controversial. A total of 682 KT patients receiving basiliximab, mycophenolic acid (MPA), corticosteroids were randomized 1:1 to cyclosporine (CsA) or tacrolimus (Tac). Risk factors were analyzed in 629 (92.2%) patients having at least 2 BKV measurements until month 12 posttransplant. Univariate analysis associated CsA-MPA with lower rates of viremia than Tac-MPA at month 6 (10.6% vs. 16.3%, p = 0.048) and 12 (4.8% vs. 12.1%, p = 0.004) and lower plasma BKV loads at month 12 (3.9 vs. 5.1 log(10) copies/mL; p = 0.028). In multivariate models, CsA-MPA remained associated with less viremia than Tac-MPA at month 6 (OR 0.60; 95% CI 0.36-0.99) and month 12 (OR 0.33; 95% CI 0.16-0.68). Viremia at month 6 was also independently associated with higher steroid exposure until month 3 (OR 1.19 per 1 g), and with male gender (OR 2.49) and recipient age (OR 1.14 per 10 years) at month 12. The data suggest a dynamic risk factor evolution of BKV viremia consisting of higher corticosteroids until month 3, Tac-MPA compared to CsA-MPA at month 6 and Tac-MPA, older age, male gender at month 12 posttransplant.
Published: 2013

31. Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients.

Author: Swiss HIV Cohort Study, Remy, B., Rickenbach, M., Schöni-Affolter, F., Vallet, Y., Francioli, MC., Barth, J., Battegay, M., Bernasconi, E., Böni, J., Bucher, HC., Burton-Jeangros, C., Calmy, A., Cavassini, M., Cellerai, C., Egger, M., Elzi, L., Fehr, J., Fellay, J., Flepp, M., Francioli, P., Furrer, H., Fux, CA., Gorgievski, M., Günthard, H., Haerry, D., Hasse, B., Hirsch, HH., Hirschel, B., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kind, C., Klimkait, T., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Metzner, K., Müller, N., Nadal, D., Pantaleo, G., Rauch, A., Rudin, C., Schmid, P., Schultze, D., Schüpbach, J., Speck, R., Taffé, P., Tarr, P., Telenti, A., Trkola, A., Vernazza, P., Weber, R., Yerly, S., Scherrer, A.U., von Wyl, V., Vernazza, P.L., Günthard, H.F., Swiss HIV Cohort Study, Remy, B., Rickenbach, M., Schöni-Affolter, F., Vallet, Y., Francioli, MC., Barth, J., Battegay, M., Bernasconi, E., Böni, J., Bucher, HC., Burton-Jeangros, C., Calmy, A., Cavassini, M., Cellerai, C., Egger, M., Elzi, L., Fehr, J., Fellay, J., Flepp, M., Francioli, P., Furrer, H., Fux, CA., Gorgievski, M., Günthard, H., Haerry, D., Hasse, B., Hirsch, HH., Hirschel, B., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kind, C., Klimkait, T., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Metzner, K., Müller, N., Nadal, D., Pantaleo, G., Rauch, A., Rudin, C., Schmid, P., Schultze, D., Schüpbach, J., Speck, R., Taffé, P., Tarr, P., Telenti, A., Trkola, A., Vernazza, P., Weber, R., Yerly, S., Scherrer, A.U., von Wyl, V., Vernazza, P.L., and Günthard, H.F.
Abstract: BACKGROUND: Minor protease inhibitor (PI) mutations often exist as polymorphisms in HIV-1 sequences from treatment-naïve patients. Previous studies showed that their presence impairs the antiretroviral treatment (ART) response. Evaluating these findings in a larger cohort is essential. METHODS: To study the impact of minor PI mutations on time to viral suppression and time to virological failure, we included patients from the Swiss HIV Cohort Study infected with HIV-1 subtype B who started first-line ART with a PI and two nucleoside reverse transcriptase inhibitors. Cox regression models were performed to compare the outcomes among patients with 0 and ≥ 1 minor PI mutation. Models were adjusted for baseline HIV-1 RNA, CD4 cell count, sex, transmission category, age, ethnicity, year of ART start, the presence of nucleoside reverse transcriptase inhibitor mutations, and stratified for the administered PIs. RESULTS: We included 1199 patients of whom 944 (78.7%) received a boosted PI. Minor PI mutations associated with the administered PI were common: 41.7%, 16.1%, 4.7% and 1.9% had 1, 2, 3 or ≥ 4 mutations, respectively. The time to viral suppression was similar between patients with 0 (reference) and ≥ 1 minor PI mutation (multivariable hazard ratio (HR): 1.1 [95% confidence interval (CI): 1.0-1.3], P = .196). The time to virological failure was also similar (multivariable HR:.9 [95% CI:.5-1.6], P = .765). In addition, the impact of each single minor PI mutation was analyzed separately: none was significantly associated with the treatment outcome. CONCLUSIONS: The presence of minor PI mutations at baseline has no effect on the therapy outcome in HIV infected individuals.
Published: 2012

32. Tuberculosis in HIV-negative and HIV-infected patients in a low-incidence country: clinical characteristics and treatment outcomes.

Author: Swiss HIV Cohort, Molecular Epidemiology of Tuberculosis Study Groups, Fenner, L., Egger, M., Gagneux, S., Tanner, M., Furrer, H., Böttger, EC., Frei, R., Bodmer, T., Ninet, B., Schrenzel, J., Jaton, K., Telenti, A., Siegrist, H., Pfyffer, GE., Bruderer, T., Dolina, M., Dubuis, O., Battegay, M., Bernasconi, E., Hoffmann, M., Cavassini, M., Hirschel, B., Calmy, A., Fehr, J., Janssens, JP., Stalder, JM., Helbling, P., Altpeter, E., Rieder, HL., Barth, J., Böni, J., Bucher, HC., Burton-Jeangros, C., Cellerai, C., Elzi, L., Fellay, J., Flepp, M., Francioli, P., Fux, CA., Gorgievski, M., Günthard, H., Haerry, D., Hasse, B., Hirsch, HH., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kind, C., Klimkait, T., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Metzner, K., Müller, N., Nadal, D., Pantaleo, G., Rauch, A., Regenass, S., Rickenbach, M., Rudin, C., Schmid, P., Schultze, D., Schöni-Affolter, F., Schüpbach, J., Speck, R., Taffé, P., Tarr, P., Trkola, A., Vernazza, P., Weber, R., Yerly, S., Janssens, J.P., Böttger, E.C., Swiss HIV Cohort, Molecular Epidemiology of Tuberculosis Study Groups, Fenner, L., Egger, M., Gagneux, S., Tanner, M., Furrer, H., Böttger, EC., Frei, R., Bodmer, T., Ninet, B., Schrenzel, J., Jaton, K., Telenti, A., Siegrist, H., Pfyffer, GE., Bruderer, T., Dolina, M., Dubuis, O., Battegay, M., Bernasconi, E., Hoffmann, M., Cavassini, M., Hirschel, B., Calmy, A., Fehr, J., Janssens, JP., Stalder, JM., Helbling, P., Altpeter, E., Rieder, HL., Barth, J., Böni, J., Bucher, HC., Burton-Jeangros, C., Cellerai, C., Elzi, L., Fellay, J., Flepp, M., Francioli, P., Fux, CA., Gorgievski, M., Günthard, H., Haerry, D., Hasse, B., Hirsch, HH., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kind, C., Klimkait, T., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Metzner, K., Müller, N., Nadal, D., Pantaleo, G., Rauch, A., Regenass, S., Rickenbach, M., Rudin, C., Schmid, P., Schultze, D., Schöni-Affolter, F., Schüpbach, J., Speck, R., Taffé, P., Tarr, P., Trkola, A., Vernazza, P., Weber, R., Yerly, S., Janssens, J.P., and Böttger, E.C.
Abstract: BACKGROUND: In Switzerland and other developed countries, the number of tuberculosis (TB) cases has been decreasing for decades, but HIV-infected patients and migrants remain risk groups. The aim of this study was to compare characteristics of TB in HIV-negative and HIV-infected patients diagnosed in Switzerland, and between coinfected patients enrolled and not enrolled in the national Swiss HIV Cohort Study (SHCS). METHODS AND FINDINGS: All patients diagnosed with culture-confirmed TB in the SHCS and a random sample of culture-confirmed cases reported to the national TB registry 2000-2008 were included. Outcomes were assessed in HIV-infected patients and considered successful in case of cure or treatment completion. Ninety-three SHCS patients and 288 patients selected randomly from 4221 registered patients were analyzed. The registry sample included 10 (3.5%) coinfected patients not enrolled in the SHCS: the estimated number of HIV-infected patients not enrolled in the SHCS but reported to the registry 2000-2008 was 146 (95% CI 122-173). Coinfected patients were more likely to be from sub-Saharan Africa (51.5% versus 15.8%, P<0.0001) and to present disseminated disease (23.9% vs. 3.4%, P<0.0001) than HIV-negative patients. Coinfected patients not enrolled in the SHCS were asylum seekers or migrant workers, with lower CD4 cell counts at TB diagnosis (median CD4 count 79 cells/µL compared to 149 cells/µL among SHCS patients, P = 0.07). There were 6 patients (60.0%) with successful outcomes compared to 82 (88.2%) patients in the SHCS (P = 0.023). CONCLUSIONS: The clinical presentation of coinfected patients differed from HIV-negative TB patients. The number of HIV-infected patients diagnosed with TB outside the SHCS is similar to the number diagnosed within the cohort but outcomes are poorer in patients not followed up in the national cohort. Special efforts are required to address the needs of this vulnerable population.
Published: 2012

33. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient

Author: Balduzzi, A, Lucchini, G, Hirsch, H, Basso, S, Cioni, M, Rovelli, A, Zincone, A, Grimaldi, M, Corti, P, Bonanomi, S, Biondi, A, Locatelli, F, Biagi, E, Comoli, P, LUCCHINI, GIOVANNA, Hirsch, HH, BIONDI, ANDREA, BIAGI, ETTORE, Comoli, P., Balduzzi, A, Lucchini, G, Hirsch, H, Basso, S, Cioni, M, Rovelli, A, Zincone, A, Grimaldi, M, Corti, P, Bonanomi, S, Biondi, A, Locatelli, F, Biagi, E, Comoli, P, LUCCHINI, GIOVANNA, Hirsch, HH, BIONDI, ANDREA, BIAGI, ETTORE, and Comoli, P.
Abstract: Progressive multifocal leukoencephalopathy (PML) associated with polyomavirus JC (JCV) infection has been reported to be usually fatal in allogeneic hematopoietic SCT (HSCT) recipients. We present the case of a 19-year-old HSCT patient diagnosed with JCV-associated PML after prolonged immunosuppression for severe GVHD. No short-term neurological improvement was observed after antiviral treatment and discontinuation of immunosuppressive therapy. Donor-derived JCV Ag-specific CTLs were generated in vitro after stimulation with 15-mer peptides derived from VP1 and large T viral proteins. After adoptive CTL infusion, virus-specific cytotoxic cells were shown in the peripheral blood, JCV-DNA was cleared in the cerebrospinal fluid and the patient showed remarkable improvement. Adoptive T-lymphocyte therapy with JCV-specific CTLs was feasible and had no side effects. This case suggests that adoptive transfer of JCV-targeted CTLs may contribute to restore JCV-specific immune competence and control PML in transplanted patients.Bone Marrow Transplantation., Progressive multifocal leukoencephalopathy (PML) associated with polyomavirus JC (JCV) infection has been reported to be usually fatal in allogeneic hematopoietic SCT (HSCT) recipients. We present the case of a 19-year-old HSCT patient diagnosed with JCV-associated PML after prolonged immunosuppression for severe GVHD. No short-term neurological improvement was observed after antiviral treatment and discontinuation of immunosuppressive therapy. Donor-derived JCV Ag-specific CTLs were generated in vitro after stimulation with 15-mer peptides derived from VP1 and large T viral proteins. After adoptive CTL infusion, virus-specific cytotoxic cells were shown in the peripheral blood, JCV-DNA was cleared in the cerebrospinal fluid and the patient showed remarkable improvement. Adoptive T-lymphocyte therapy with JCV-specific CTLs was feasible and had no side effects. This case suggests that adoptive transfer of JCV-targeted CTLs may contribute to restore JCV-specific immune competence and control PML in transplanted patients. Bone Marrow Transplantation (2011) 46, 987-992; doi: 10.1038/bmt.2010.221; published online 4 October 2010
Published: 2011

34. Erythema migrans: Dauer der antibiotischen Therapie?

Author: Hirsch Hh and Quadranti P
Subjects: General Medicine
Abstract: Selbsteinweisung eines 59-jährigen Patienten mit einer Hautveränderung von 12 cm Durchmesser über der rechten Flanke, die als Erythema migrans imponierte und mit einer 10-tägigen Therapie mit Doxycyclin behandelt wurde. In der Nachkontrolle wurde gemäss der obengenannten Studiendefinition ein vollständiges Ansprechen beobachtet.
Published: 2005
Full Text: View/download PDF

35. Erfolgreiche Therapie einer schweren Parvovirus-B19-induzierten hyporegeneratorischen Anämie nach Nierentransplantation mit IVIG

Author: Goldwasser, R, primary, Kiepe, D, additional, Höcker, B, additional, Schnitzler, P, additional, Hirsch, HH, additional, and Tönshoff, B, additional
Published: 2011
Full Text: View/download PDF

36. Neuraminidasehemmer - Fokus: Oseltamivir

Author: Tschudin Sutter, S, primary, Hirsch, HH, additional, Battegay, M, additional, and Widmer, AF, additional
Published: 2010
Full Text: View/download PDF

37. Inhibiteurs des neuraminidases au centre: oseltamivir

Author: Tschudin Sutter, S, primary, Hirsch, HH, additional, Battegay, M, additional, and Widmer, AF, additional
Published: 2010
Full Text: View/download PDF

38. Neue Diagnostik in der Transplantationsmedizin: Cytomegalovirus-(CMV-)spezifische T-Zellfrequenz und Ganciclovir-Resistenzanalyse

Author: Egli, A, primary, Dumoulin, A, additional, Kiss, D, additional, and Hirsch, HH, additional
Published: 2008
Full Text: View/download PDF

39. Recommandations suisses pour la prise en charge des infections dues au virus de la varicelle-zoster

Author: Kempf, W, primary, Meylan, P, additional, Gerber, S, additional, Aebi, C, additional, Agosti, R, additional, Büchner, S, additional, Coradi, B, additional, Garweg, J, additional, Hirsch, HH, additional, Kind, C, additional, Lauper, U, additional, Lautenschlager, S, additional, Reusser, P, additional, Ruef, C, additional, Wunderli, W, additional, and Nadal, D, additional
Published: 2007
Full Text: View/download PDF

40. Schweizer Empfehlungen für das Management der Varicella-Zoster-Virus-Infektion

Author: Kempf, W, primary, Meylan, P, additional, Gerber, S, additional, Aebi, C, additional, Agosti, R, additional, Büchner, S, additional, Coradi, B, additional, Garweg, J, additional, Hirsch, HH, additional, Kind, C, additional, Lauper, U, additional, Lautenschlager, S, additional, Reusser, P, additional, Ruef, C, additional, Wunderli, W, additional, and Nadal, D, additional
Published: 2007
Full Text: View/download PDF

41. Qui est en danger en cas de pandémie de grippe?

Author: Krapf, R, primary and Hirsch, HH, additional
Published: 2007
Full Text: View/download PDF

42. Wer ist bei einer Influenzapandemie gefährdet?

Author: Krapf, R, primary and Hirsch, HH, additional
Published: 2007
Full Text: View/download PDF

43. Alte Viren - Neue Immunsuppressiva: liaison dangereuse?

Author: Hirsch, HH, primary, Dickenmann, M, additional, Binggeli, S, additional, and Steiger, J, additional
Published: 2004
Full Text: View/download PDF

44. Virological Outcome and Management of Persistent Low-Level Viraemia in HIV-1-Infected Patients: 11 Years of the Swiss HIV Cohort Study

Author: Boillat-Blanco, Noémie, Darling, Katharine EA, Schoni-Affolter, Franziska, Vuichard, Danielle, Rougemont, Mathieu, Fulchini, Rosamaria, Bernasconi, Enos, Aouri, Manel, Clerc, Olivier, Furrer, Hansjakob, Günthard, Huldrych F, Cavassini, Matthias, Aubert, V, Battegay, M, Bernasconi, E, Böni, J, Bucher, HC, Burton-Jeangros, C, Calmy, A, Cavassini, M, Dollenmaier, G, Egger, M, Elzi, L, Fehr, J, Fellay, J, Furrer, H, Fux, CA, Gorgievski, M, Günthard, H, Haerry, D, Hasse, B, Hirsch, HH, Hoffmann, M, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, R, Kovari, H, Ledergerber, B, Martinetti, G, Martinez, De Tejada B, Metzner, K, Müller, N, Nadal, D, Nicca, D, Pantaleo, G, Rauch, A, Regenass, S, Rickenbach, M, Rudin, C, Schöni-Affolter, F, Schmid, P, Schüpbach, J, Speck, R, Tarr, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, and Yerly, S
Abstract: Background Management of persistent low-level viraemia (pLLV) in patients on combined antiretroviral therapy (cART) with previously undetectable HIV viral loads (VLs) is challenging. We examined virological outcome and management among patients enrolled in the Swiss HIV Cohort Study (SHCS).Methods In this retrospective study (2000–2011), pLLV was defined as a VL of 21–400 copies/ml on = three consecutive plasma samples with =8 weeks between first and last analyses, in patients undetectable for =24 weeks on cART. Control patients had = three consecutive undetectable VLs over =32 weeks. Virological failure (VF), analysed in the pLLV patient group, was defined as a VL>400 copies/ml.Results Among 9,972 patients, 179 had pLLV and 5,389 were controls. Compared to controls, pLLV patients were more often on unboosted protease inhibitor (PI)-based (adjusted odds ratio [aOR; 95% CI] 3.2 [1.8, 5.9]) and nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)-only combinations (aOR 2.1 [1.1, 4.2]) than on non-nucleoside reverse transcriptase inhibitor and boosted PI-based regimens. At 48 weeks, 102/155 pLLV patients (66%) still had pLLV, 19/155 (12%) developed VF and 34/155 (22%) had undetectable VLs. Predictors of VF were previous VF (aOR 35 [3.8, 315]), unboosted PI-based (aOR 12.8 [1.7, 96]) or NRTI-only combinations (aOR 115 [6.8, 1,952]), and VLs>200 during pLLV (aOR 3.7 [1.1, 12]). No VF occurred in patients with persistent very LLV (21-49 copies/ml; n=26). At 48 weeks, 29/39 patients (74%) who changed cART had undetectable VLs, compared with 19/74 (26%) without change (P<0.001).Conclusions Among patients with pLLV, VF was predicted by previous VF, cART regimen and VL=200. Most patients who changed cART had undetectable VLs 48 weeks later. These findings support cART modification for pLLV>200 copies/ml.
Published: 2015
Full Text: View/download PDF

45. Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.

Author: Kuhle J, Gosert R, Bühler R, Derfuss T, Sutter R, Yaldizli O, Radue EW, Ryschkewitsch C, Major EO, Kappos L, Frank S, Hirsch HH, Kuhle, J, Gosert, R, Bühler, R, Derfuss, T, Sutter, R, Yaldizli, O, Radue, E-W, and Ryschkewitsch, C
Published: 2011
Full Text: View/download PDF

46. Die elektrophysiologischen Voraussetzungen des ventrikel-gesteuerten Herzschrittmachers

Author: Stauch M and Hirsch Hh
Subjects: Pulmonary and Respiratory Medicine, Gynecology, medicine.medical_specialty, business.industry, Medicine, Surgery, Cardiology and Cardiovascular Medicine, business
Published: 1967
Full Text: View/download PDF

47. Störungen bei der Verwendung des ventrikelgesteuerten Herzschrittmachers

Author: Eisenbach J, Hirsch Hh, and Pocai Br
Subjects: Pulmonary and Respiratory Medicine, medicine.medical_specialty, Text mining, medicine.anatomical_structure, business.industry, Ventricle, Internal medicine, Cardiology, Medicine, Surgery, Cardiology and Cardiovascular Medicine, business
Published: 1968
Full Text: View/download PDF

48. Komplikationen bei der Schrittmacherimplantation

Author: Eisenbach J, Hirsch Hh, and Scior H
Subjects: Pulmonary and Respiratory Medicine, medicine.medical_specialty, business.industry, MEDLINE, Medicine, Surgery, Cardiology and Cardiovascular Medicine, business, Pacemaker implantation
Published: 1966
Full Text: View/download PDF

49. Extra- oder intrathorakale Herzmassage beim akuten Kreislaufstillstand

Author: Hartel W, Hirsch Hh, and Ungeheuer E
Subjects: Pulmonary and Respiratory Medicine, medicine.medical_specialty, Heart block, business.industry, Carotid arteries, Femoral artery, medicine.disease, Internal medicine, medicine.artery, medicine, Cardiology, Surgery, Heart massage, Cardiology and Cardiovascular Medicine, business
Published: 1963
Full Text: View/download PDF

50. Spülung durch den Blutstrom als Ursache der Beständigkeit des homologen Herzklappengewebes nach der Transplantation

Author: Hirsch Hh and Hanke H
Subjects: Pulmonary and Respiratory Medicine, Aortic valve, medicine.medical_specialty, business.industry, medicine.anatomical_structure, Internal medicine, medicine, Homologous chromosome, Cardiology, Flushing, Surgery, medicine.symptom, Cardiology and Cardiovascular Medicine, business, Blood stream
Published: 1969
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

554 results on '"Hirsch, HH."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources